Introduction {#s1}
============

The cardiac action potential is critical to proper heart function. Beginning with the activation of "pacemaker" cells, the action potential propagates through the atria and into the ventricles in a unidirectional waveform of excitation and relaxation, resulting in the coordinated expansion and contraction of heart tissue ([@B198]). The action potential is governed by an intricate series of ion channel activities ([@B84]), including those of the KCNQ1 (K~V~LQT1, K~V~7.1) and hERG (KCNH2, K~V~11.1) potassium channels and the SCN5A (Na~V~1.5) sodium channel. Mutations in these three channels are the most frequent cause of congenital long QT syndrome (LQTS), a cardiac arrhythmia disorder that is one of the primary causes of sudden arrhythmic death syndrome (SADS) ([@B256]).

KCNQ1, hERG, and SCN5A each play a distinct role in generating the cardiac action potential ([**Figure 1**](#f1){ref-type="fig"}), consequently producing distinct LQTS forms when mutated ([@B256]). The initial upstroke is governed primarily by SCN5A, producing the I~Na~ current that amplifies membrane depolarization and propagates the action potential ([@B187]; [@B256]). Mutation in SCN5A causes LQTS type 3 (LQT3). hERG shapes both the plateau and the repolarization phases of the action potential, along with KCNQ1 in complex with the KCNE1 accessory protein ([@B187]; [@B76]). hERG and the KCNQ1--KCNE1 complex produce the rapid (I~Kr~) and slow (I~Ks~) delayed rectifier currents ([**Figures 1B, C**](#f1){ref-type="fig"}), respectively. KCNQ1 mutation causes LQT1, and hERG, LQT2 ([@B256]). Additional ion channels and transporters also shape the cardiac action potential ([@B256]), among them Ca~v~1.2, NCX1, and Kir2.1. The roles of these channels in the cardiac action potential and cardiac arrhythmias have been reviewed elsewhere ([@B25]; [@B88]; [@B179]; [@B282]; [@B150]). These channels are not typically causative for LQTS and will not be discussed here.

![Voltage-activated Na^+^ and K^+^ currents define the ventricular action potential and QT interval of the ECG. **(A)** ECG trace. The rapid upstroke of the ventricular action potential gives rise to the QRS complex. The duration of the QT interval is determined by the time of the ventricular repolarization. **(B)** Trace of the ventricular action potential. The rapidly activating and inactivating I~Na~ current drives membrane depolarization. Two K^+^ currents, I~Ks~ and I~Kr~, contribute most to the plateau phase and repolarization phase of the action potential, which reestablishes the membrane resting potential. **(C)** Time course of I~Na~, I~Kr~, and I~Ks~ currents (not drawn to scale). Currents of other ion channels contributing to the action potential (e.g. I~Ca,L~, I~Kur~, and I~NCX~) are not shown for clarity. This figure is inspired by figures in [@B187] and [@B76].](fphar-11-00550-g001){#f1}

Structurally, the KCNQ1, hERG, and SCN5A channels belong to the voltage-gated ion channel superfamily and share a general transmembrane topology ([@B21]; [@B57]). The transmembrane channel domain is composed of six helices per subunit in hERG and KCNQ1 ([**Figures 2A, B**](#f2){ref-type="fig"}) or a monomeric tetrad repeat of linked 6-helix domains for SCN5A, each repeat exhibiting varying sequences, lengths, and tertiary folds ([**Figures 2C, D**](#f2){ref-type="fig"}). The assembled channel is tetrameric (pseudo-tetrameric for SCN5A), with each channel domain composed of four voltage sensing domains (VSDs) surrounding a central pore domain (PD) ([**Figure 2D**](#f2){ref-type="fig"}). The VSD is comprised of the first four transmembrane helices (S1--S4) preceded by a small amphipathic helix---S0---in both KCNQ1 and SCN5A ([@B116]; [@B264]). The PD is formed by the tetramerization of S5 and S6 helices from each subunit/repeat ([**Figure 2D**](#f2){ref-type="fig"}). A pore loop between S5 and S6 contains the selectivity filter (SF) that confers ion specificity. A linker helix between helices S4 and S5, termed the S4--S5 linker, connects the VSD to the PD ([@B21]; [@B57]) ([**Figures 2A--C**](#f2){ref-type="fig"}).

![Overall topology of KCNQ1, hERG, and SCN5A channels. **(A)** KCNQ1 topology. Transmembrane domain alpha helices are labeled S0--S6. PH indicates the pore helix. SF denotes the selectivity filter. S2--S3 indicates the S2--S3 linker. S4--S5 denotes the S4--S5 linker. Cytosolic alpha helices are labeled HA-HD. **(B)** hERG topology. PAS denotes the Per-ARNT-Sim domain. CNBHD indicates the C-terminal cyclic nucleotide-binding homology domain. **(C)** SCN5A topology. CTD indicates the C-terminal domain. **(D)** Top views of the human KCNQ1 (PDB ID: 6UZZ) ([@B264]), human hERG (PDB ID: 5VA1) ([@B294]), and rat SCN5A (PDB ID: 6UZ3) ([@B116]) channels, respectively. Outer voltage-sensing domains (VSD) and the central pore domain (PD) are labeled.](fphar-11-00550-g002){#f2}

Given these similarities in channel topology and components, how is it that KCNQ1, hERG, and SCN5A perform such distinct functions, and produce phenotypically distinct forms of LQTS? To explore this question, a number of high-resolution ion channel structures, including cryo-electron microscopy (cryo-EM) structures of frog and human KCNQ1 ([@B264]) and of human hERG ([@B294]), as well as the structures of the rat homolog of SCN5A ([@B116]) and human Na~v~1 isoforms Nav1.4 and 1.7 ([@B205]; [@B252]; [@B317]), have been determined. Moreover, the frog KCNQ1 structure has been used to develop what is likely a reliable homology model for the human KCNQ1 channel in resting and fully active conformations ([@B138]). A homology model of human SCN5A in the resting state has also been devised ([@B137]). These structures and structural models reveal critical differences in the atomic details of KCNQ1, hERG, and SCN5A structures associated with their distinct functions and disease phenotypes. Notably, the subunits of KCNQ1 undergo domain swapping, with a similar arrangement observed in SCN5A but not in the hERG channel ([**Figure 2D**](#f2){ref-type="fig"}). The monomeric sequence of SCN5A causes the channel to adopt an asymmetric three-dimensional fold, in contrast to the inherent symmetry of tetrameric hERG and KCNQ1 ([**Figure 2D**](#f2){ref-type="fig"}). Additionally, the C-terminal domains contain distinct folds and mediate unique regulatory functions. These and other structural differences contribute to the varying properties of these three channels and to their distinct roles in the cardiac action potential.

The aim of this review is to compare and contrast the KCNQ1, hERG, and SCN5A channels using available structures and structural models as a guide. Through this lens, channel gating, regulation, LQTS mechanisms, and pharmacology will be discussed, in order to explore the molecular basis of these unique properties.

Structural Mechanisms of Channel Gating {#s2}
=======================================

KCNQ1, hERG, and SCN5A undergo conformational changes in response to changes in membrane potential that result in channel opening or closing. These responses confer specific gating properties including activation, deactivation, inactivation, and recovery from inactivation ([@B101]; [@B331]). In activation, protein conformational changes result in channel pore opening from a resting state, while deactivation entails a return to the resting state ([@B331]). Inactivation confers a third channel state distinct from the activated and resting states which inhibits current flow prior to full deactivation ([@B331]). While all three channels share common structural elements that are responsible for producing these states, there are also elements that give rise to specific gating properties in each channel, as discussed below.

Activation and Ion Conduction {#s2_1}
-----------------------------

### KCNQ1 {#s2_1_1}

Voltage-gated channels contain up to six positively-charged basic residues in the S4 helix, called gating charges, which move in the electric field of the membrane in response to voltage ([@B115]). Gating charges are numbered according to their position in the S4 helix, from the extracellular to the intracellular side. In KCNQ1, S4 contains four arginine (R) gating charges that are conserved in other K~V~ channels and confer voltage sensitivity. However, in KCNQ1 the canonical R3 is replaced by a neutral glutamine (Q234, Q3), and the fifth gating charge (K5 in Shaker) is replaced by histidine (H241, H5), which in the membrane environment is expected to be neutral at physiological pH ([**Figures 3A, B**](#f3){ref-type="fig"}). Due to these substitutions at positions 3 and 5, the S4 helix of KCNQ1 has a lower net positive charge (+4) than Shaker-class K^+^ channels, such as K~V~1.2 (+6). The lower net positive charge may explain why KCNQ1 S4 mutations that result charge loss or reversal ([@B207]; [@B310]) result in constitutive channel activity.

![The voltage sensors of KCNQ1, hERG, and SCN5A. **(A)** Structure of the VSD from human KCNQ1 (left) (PDB: 6UZZ) ([@B264]) and hERG (right) (PDB: 5VA2) ([@B294]) in putative activated conformations. Basic residues on S4 (labeled in blue), acidic residues on S2 and S3 (labeled in red), and the phenylalanine residue in the gating charge transfer center (purple) are shown as sticks. The first four basic residues on S4 (R1--R4) in KCNQ1 and the first three (K1--R3) in hERG are located above the charge transfer center. **(B)** Multiple sequence alignment of VSDs I-IV of SCN5A with the VSDs of human KCNQ1 and hERG. Basic residues in S4 implicated with voltage sensing are colored blue, and acidic or polar residues in S1--S3 suggested to interact with S4 gating charges are colored red. The conserved aromatic residue at the gating charge transfer center in S2 is colored purple. Another tryptophan residue in S3, conserved in the VSDs of Na~V~ channels and also present in hERG, is colored green.](fphar-11-00550-g003){#f3}

Voltage-gated channels also feature a charge transfer center (CTC), formed by a bulky aromatic ring and two negatively charged residues, that facilitates S4 movement ([@B266]). The KCNQ1 CTC consists of E170 (E2) and F167 on S2, and D202 on S3, which work with E160 (E1) to define the S4 position. During activation, S4 moves towards the extracellular side of the membrane ([@B194]; [@B228]; [@B203]; [@B231]; [@B17]; [@B195]; [@B18]) through interactions between basic gating charges and E1 and E2 in the CTC ([**Figure 3A**](#f3){ref-type="fig"}). These interactions change during the course of activation, permitting S4 translocation. E1 interacts with R1 (R228) or R4 (R237) in the resting and activated states of the VSD, respectively ([@B309]). S4 motion occurs in two distinct steps, transitioning through a stable intermediate before reaching the activated state ([@B309]; [@B17]; [@B327]). The intermediate state features salt bridge interactions between E1 and R2, distinct from the resting and activated VSD states, according to the recently-determined structure of the intermediate state KCNQ1 VSD ([@B269]). Interestingly, the pore of KCNQ1 opens in both the intermediate state (IO) and fully activated (AO) states ([@B327]). These two open states possess distinct channel properties with differing opening probabilities and pharmacology ([@B102]), and have distinct pore structures ([@B327]). Importantly, ion conductance when the VSD is in either the intermediate or activated state appears to be unique to KCNQ1. However, formation of the KCNQ1--KCNE1 complex eliminates the conductance associated with the VSD intermediate state ([@B327]), such that I~Ks~ reflects only the fully activated state.

The ion conduction pathway in KCNQ1 is lined by the four S6 helices, with the SF on the extracellular side of the pore. Mutations in S6 cause changes in current amplitude and voltage dependence of activation ([@B295]; [@B246]; [@B208]; [@B98]). Comparison of S6 in the closed pore structure of human KCNQ1 ([@B264]) with that of the open channel demonstrates that channel opening results from bending of S6 so that the cytosolic ends of the four S6 segments swing away from the central axis, enlarging the diameter of the pore to allow diffusion of K^+^ into the central cavity. The hinge responsible for this bending motion in S6 is the P343--A344--G345 (PAG) motif, which corresponds to PVP in Shaker K^+^ channels ([@B140]). Additionally, A336 may also be important in the motion of the activation gate, as mutations at this position alter the voltage dependence of activation ([@B247]).

Once the intracellular gate is opened, K^+^ ions move through the pore along their electrochemical gradient. The backbone carbonyl oxygens of the TIGYG motif in the SF of KCNQ1 (TVGYG in K~V~1.2 and KcsA) ([**Figure 4A**](#f4){ref-type="fig"}) and the sidechain of T312 form four evenly spaced K^+^ binding sites ([**Figure 4B**](#f4){ref-type="fig"}) that facilitate K^+^ movement ([@B334]). The arrangement of these oxygens mimics the displaced hydration shell of K^+^, which lowers the transfer energy from the aqueous cavity at the center of the channel to the SF, allowing conduction to occur at rates near the diffusion limit ([@B183]; [@B334]).

![The selectivity filters of K^+^ and Na^+^ channels. **(A)** Multiple sequence alignment of the SF region of selected K^+^ (left) and Na^+^ (right) channels. Conserved amino acids are highlighted in bold. Amino acids belonging to the DEKA signature motif in eukaryotic Na^+^ channels are colored red. **(B)** Side and top view of the SF of human KCNQ1 (PDB: 6UZZ) ([@B264]). Two subunits are omitted for clarity in the left plot. **(C)** Side and top view of the SF of SCN5A (PDB: 6UZ3) ([@B116]). Repeat II is omitted for clarity in the left plot.](fphar-11-00550-g004){#f4}

### hERG {#s2_1_2}

The cryo-EM structure of hERG shows an open pore and activated VSDs, with the first three gating charges (K1--R3) of S4 located on the extracellular side of the CTC ([**Figure 3A**](#f3){ref-type="fig"}). This is a translocation of one charge fewer than in the activated VSD of KCNQ1 ([@B263]) and Shaker-like K~V~1.2--2.1 ([@B158]) where four gating charges are located above the conserved phenylalanine in the CTC. This observation agrees with gating current measurements suggesting a total charge movement of only \~6 elementary charge units (movement of 1.5 positive charges per S4 helix) for hERG during activation ([@B330]), compared to 8 to 9 (2 positive charges per helix) for KCNQ1 ([@B231]) and 12 to 16 (3--4 positive charges per helix) for Shaker-like K~V~ channels ([@B236]; [@B6]; [@B249]). However, the ca. 50% lower total gating charge movement for hERG relative to Shaker-like channels is not explained by differences in the number of S4 gating charges, since hERG has a total of five positively-charged residues on S4 and Shaker has six ([@B216]). These combined structural and functional data thus imply that S4 translocates less in hERG during activation, resulting in smaller overall VSD conformational changes.

However, the activated VSD of hERG may not be fully defined. While the position of K1--R3 above the CTC in the cryo-EM structure of hERG is consistent with a depolarized VSD, some salt bridge interactions in the VSD have suboptimal geometry, particularly with R4. This is likely due to the limited resolution of the VSD in the final map (approximately 4.5--5.5 Å) ([@B294]), impeding unambiguous determination of sidechain conformations. While cryo-EM has proven to be a powerful structural tool, the resolution is often lower in the periphery of protein structures ([@B96]). This can prevent accurate modeling of functional features and lead to discrepancies with experimental data. Molecular dynamics may be a be useful tool in refining cryo-EM structures to mitigate these discrepancies, as is currently being carried out for the hERG structure ([@B130]).

While a structure of hERG with a closed PD has not yet been determined, we can gain insight into the conformational changes that occur during pore opening using the closed-pore structure of the closely related rat potassium voltage-gated subfamily H member 1 channel (EAG1 or KCNH1) ([@B303]). In hERG, the intracellular gate is likely constricted by the Q664 side chains in S6, since the radius of the cavity at Q664 is almost 6 Å in the open state hERG structure ([@B294]), while at the corresponding position (Q476) in the EAG1 closed state structure, the pore is at its narrowest (\< 1 Å) ([@B303]). Bending and displacement of the S6 helices is suggested by a glycine residue, located at the same position in both channels, acting as a gating hinge (G648 in hERG, G460 in EAG1).

The SF in hERG is unique among K~v~ channels, containing a GFG motif ([**Figure 4A**](#f4){ref-type="fig"}) in place of the typical GYG motif ([@B157]). The position of the phenylalanine residue in this motif is different from the corresponding tyrosine in other K~v~ channels of known structure ([@B294]). This structural variation may have important implications for fast inactivation in hERG, as discussed below.

### SCN5A {#s2_1_3}

The mechanism of voltage sensing in Na~V~ channels is thought to be similar to that of K~V~ channels. The S4 helix is the key sensor of transmembrane voltage. Pairing of the positively-charged residues in S4 with polar or negatively-charged residues catalyzes S4 movement from its inward resting-state position to the outward activated state upon membrane depolarization. Recent cryo-EM structures of Na~V~ channels with VSDs in activated ([@B319]; [@B205]; [@B206]; [@B252]; [@B116]) and resting ([@B51]; [@B306]; [@B317]) conformations uncover a remarkable 10 to 15 Å translation of S4 across the membrane, fully consistent with the "sliding helix" model of VSD activation ([@B37]). A conserved aromatic residue (tyrosine in repeat I, phenylalanine II, III, and IV) on S2 serves as the hydrophobic plug that constricts the S4 gating canal and prevents ion leak through the VSD ([@B116]). This hydrophobic plug is mechanistically identical to the corresponding residues in the CTC of K~V~ channels (F167 in KCNQ1, F463 in hERG). However, in contrast to the VSD of KCNQ1 and hERG, the number of basic residues on S4 in SCN5A varies from four (repeat I) to six (repeat IV) ([@B116]) ([**Figure 3B**](#f3){ref-type="fig"}). The variation in the number of gating charges and the heterogenous distribution of acidic and polar residues on S1--S3 between KCNQ1, hERG, and SCN5A ([**Figure 3B**](#f3){ref-type="fig"}) may be responsible for their distinct voltage sensitivities and kinetics of VSD activation. In Na~V~ channels, the VSDs of repeats I, II, and III are mainly responsible for channel activation and pore opening, while the VSD of repeat IV is responsible for initiating and maintaining fast inactivation ([@B41]; [@B36]; [@B51]). This activation process has been studied in detail for the human skeletal muscle channel Na~V~1.4, giving rise to the "asynchronous gating model" ([@B41]; [@B36]; [@B82]) wherein the S4 segments of repeats I, II, and III move quickly, permitting conductance before activation of VSD~IV~, while S4 movement in repeat IV is slower and represents the rate-limiting step for development of and recovery from inactivation.

The structure and function of the selectivity filter in SCN5A and other Na~V~ channels differs fundamentally from that of K~V~ channels such as KCNQ1 and hERG ([**Figure 4**](#f4){ref-type="fig"}). The SF gate in Na~V~ channels is wider to allow Na^+^ ions to pass in a partially hydrated state ([@B97]; [@B196]). The extracellular vestibule of Na~V~ channels is lined by negatively-charged residues that recruit Na^+^ ions to the SF. Coordination by both sidechain and backbone carbonyls contribute to the Na^+^ permeation mechanism ([@B39]; [@B280]; [@B196]). Additionally, the SF of eukaryotic Na~V~ channels is formed in a pseudo-symmetric fashion by four short helix-connecting turn motifs from each subunit ([**Figure 4A**](#f4){ref-type="fig"}). Four distinct residues--DEKA, one in each repeat-form the signature motif for Na^+^ selectivity found in all human Na~V~ channel pore-forming repeats ([**Figure 4C**](#f4){ref-type="fig"}). The lysine residue in the DEKA motif (K1419 in SCN5A) confers selectivity for Na^+^ and prevents permeability of Ca^2+^ ([@B65]). The recent rat SCN5A structure suggests a mechanism by which K1419 contributes to this selectivity of Na^+^ over Ca^2+^, whrein lysine forms a charge delocalization network at a constriction point in the SF. Only Na^+^ ions, which have a compatible size and electric field strength, are able to pass through ([@B116]).

Electromechanical Coupling {#s2_2}
--------------------------

### KCNQ1 {#s2_2_1}

In the absence of accessory subunits, KCNQ1 exhibits a constitutive current reflecting close-to-open state transitions even at very negative (\~−120 mV) voltages ([@B164]). Analysis of a large group of KCNQ1 mutants suggests that gating follows an allosteric model ([@B164]). According to this model, the pore can open independently of the state of the VSD, but VSD activation increases the probability of pore opening. Furthermore, KCNQ1 opening does not require concerted VSD movements ([@B204]). Indeed, the VSDs appear to move independently, and pore opening can occur before all VSDs are activated ([@B204]), consistent with an allosteric gating model.

Allosteric coupling for KCNQ1 is thought to be mediated by interactions between the VSD and the PD that translate S4 movement to channel opening and closing ([**Figure 5**](#f5){ref-type="fig"}). Studies of KCNQ1 ([@B31]; [@B141]) and of other K~V~ channels ([@B162]; [@B163]; [@B157]) have pointed to the interface between the S4--S5 linker and the C-terminal end of S6 (S6~C~) as one important mediator of electromechanical coupling ([**Figure 5A**](#f5){ref-type="fig"}). Certain mutations in the S4--S5 linker ([@B141]) and S6~C~ ([@B31]) slow the opening rate and shift channel activation to more depolarized voltages, while other mutations, specifically at V254 in the S4--S5 linker and at L353 in S6~C~, promote a constitutively open channel. Interestingly, a V254L/L353A double mutant rescued channel closing, suggesting that the S4--S5 linker interacts with S6~C~ to stabilize the closed state. Relocation of the S4--S5 linker during gating abolishes this interaction, releasing tension on S6 and allowing it to kink at the PAG gating hinge in a cantilever-like fashion to promote channel opening ([**Figure 5B**](#f5){ref-type="fig"}). This coupling mechanism is intrinsically weak for KCNQ1, requiring modulation by auxiliary molecules (see below). Recent work has further elucidated the molecular details of S4--S5 linker relocation, revealing a two-stage mechanism involving alternative binding modes of the S4--S5 linker to the PD ([@B104]). This two-stage mechanism may apply to the majority of domain-swapped K~v~ channels.

![Structural features of electromechanical coupling in the KCNQ1 and hERG channels. **(A)** Left: Extracellular view of KCNQ1 and hERG transmembrane segments S0 to S6. Individual subunits are drawn with different colors. KCNQ1 (PDB: 6UZZ) ([@B264]) has a domain-swapped architecture whereas hERG (PDB: 5VA1) ([@B294]) channels are non-domain-swapped. Right: Cartoon representation of a single subunit and its neighboring pore segments (S5 to S6). In KCNQ1, the VSD and PD are bridged by an extended α-helical S4--S5 linker, whereas in hERG, S4 and S5 are connected by only a short helix. **(B)** Implications for the direction of coupled motions between the VSD and PD based on molecular modeling of KCNQ1 in open and closed conformations (top) and comparison of the open state structure of hERG with the closed state structure of EAG1 (PDB: 5K7L) ([@B303]) (bottom). In the domain-swapped KCNQ1 channel, the S4 movement is transmitted to the gate through the S4--S5 linker. In hERG and EAG1, the S4 movement is proposed to exert a direct force on the S5--S6 interface to compress or open the channel gate.](fphar-11-00550-g005){#f5}

### hERG {#s2_2_2}

The relative positioning of the VSD and PD in hERG ([@B294]) ([**Figure 5A**](#f5){ref-type="fig"}) and the EAG1 channel ([@B303]) suggests that the mechanism by which movements in the VSD are transduced to pore opening is different from other K~V~ channels ([@B278]; [@B16]). This notion is supported by the finding that cutting the S4--S5 linker in hERG through separate expression of the VSD and PD fails to significantly perturb activation kinetics ([@B160]). In contrast to the lever mechanism proposed for KCNQ1, lateral S4 movement in hERG toward the pore could both alter S4--S5 linker/S6 interactions and exert force through the S4--S5 linker directly onto S5. Displacement of S5 may be transmitted through the S5--S6 interface for opening or closing of the cytosolic gate ([@B294]) ([**Figure 5B**](#f5){ref-type="fig"}). A structure of hERG in the resting state may provide further insight into the molecular features of this distinct coupling mechanism.

### SCN5A {#s2_2_3}

Much of our knowledge about the coupling in SCN5A originates from studies of ancestral Na~V~ channels. Comparison of locked resting state structures of the bacterial sodium channel Na~V~Ab ([@B306]) and of the chimeric human Na~V~1.7--VSD~II~--Na~V~Ab channel ([@B317]) with activated state structures ([@B319]; [@B205]; [@B206]; [@B252]; [@B116]) provide new insight into the mechanism of electromechanical coupling in Na~V~ channels. The S4--S5 linker appears to undergo movement similar to that of KCNQ1. The linker constrains the S5 and S6 helices in the resting/closed state, with looser interactions in the activated/open state. Coupling between the VSD and PD during pore opening must involve loosening of linker/PD interactions as S4 moves outward as in KCNQ1, albeit with tighter coupling of S4 and S4--S5 linker movement. The direct connection between S4 movement and pore opening may be crucial for rapid activation of sodium channels.

Comparison of the cockroach Na~V~PaS channel structure ([@B251]), featuring a closed pore and VSDs in distinct activation states, to other eukaryotic Na~V~ channel structures suggests that additional structural shifts may be at work in eukaryotic Na~V~ channels to couple VSD to PD movement. Moreover, the distinct sequence of repeats I to IV (including that of the four S4--S5 linkers) and asynchronous voltage sensor movement in eukaryotic Na~V~ channels ([@B41]) suggest that distinct interactions couple the VSD of each repeat to the PD. Electromechanical coupling mechanisms may thus be more complex in SCN5A.

Inactivation {#s2_3}
------------

### KCNQ1 {#s2_3_1}

Inactivation in KCNQ1 follows a mechanism distinct from canonical mechanisms ([@B102]). In the absence of KCNE1, KCNQ1 only partially inactivates, in a manner dependent on the IO and AO open states ([@B220]). Differences in VSD-PD coupling between these two states appear to contribute to inactivation. The AO state has a lower coupling efficiency than IO, producing a lower open probability. Transition from IO to AO thus results in partial inactivation because the channel is open but less conductive ([@B102]). However, association with the KCNE1 accessory β subunit removes KCNQ1 inactivation ([@B220]; [@B245]), making inactivation irrelevant to cardiac KCNQ1 function.

### hERG {#s2_3_2}

Inactivation plays a critical role in hERG activity in the action potential. Entry into and out of inactivation is both fast and voltage-dependent, properties that maintain the plateau of the action potential ([@B213]). Additionally, the voltage dependence of inactivation appears to be independent of that of activation ([@B285]; [@B47]), indicating that activation and inactivation may operate through distinct mechanisms. Inactivation in hERG is C-type ([@B257]), occurring through structural changes in the SF ([@B95] 14243; [@B99]). While the structural basis of C-type inactivation is not completely understood, work on hERG and other K^+^ channels has provided useful insight. Several residues in the KcsA SF form stabilizing hydrogen bond networks that suppress inactivation ([@B61]; [@B22]; [@B54]; [@B286]). While these residues are conserved in many K~v~ channels ([@B303]), they are not present in hERG. This implies that the hERG SF is more liable to collapse, leading to inactivation ([@B64]; [@B286]). Indeed, in molecular dynamics simulations, several residues in the hERG SF shift in and out of the pore axis, particularly F627 in the GFG motif ([@B260]). In the hERG cryo-EM structure, the orientation of F627 is offset compared to other K~v~ channels ([@B303]), and a hERG S631A mutant, which has an F627 sidechain orientation similar to other structures, does not inactivate ([@B294]). Additionally, mutation of T432 and A443 (corresponding to S620 and S631 in hERG) in non-inactivating EAG1 to serine was sufficient to impart inactivation behavior ([@B69]), perhaps due to reorientation of the SF to match that of hERG. These results indicate that the unique positioning of F627 is critical for hERG fast inactivation behavior. C-type inactivation may involve other rearrangements ([@B159]), including coupling the SF to motions in S1, S5, and S6 ([@B66]; [@B298]; [@B211]; [@B212]).

### SCN5A {#s2_3_3}

Fast inactivation in SCN5A halts inward Na^+^ current triggered by cardiac depolarization, permitting subsequent outward currents (e.g. I~Ks~, I~Kr~) to repolarize the cell in preparation for the next action potential ([@B78]) ([**Figure 6A**](#f6){ref-type="fig"}). The S4 segment in VSD~IV~ (S4~IV~) is critical for fast inactivation, along with the IFM motif in the III/IV linker ([@B7]; [@B78]) ([**Figures 6B, C**](#f6){ref-type="fig"}). Roles of individual basic sites of S4~IV~ in Na~v~ inactivation have been elucidated, with mutations in R1 and R2 delaying inactivation onset and mutations in R3 and R4 delaying recovery from inactivation ([@B193]). Furthermore, structures of an engineered human Na~V~1.7--Na~V~PaS channel with VSD~IV~ trapped in a resting state ([@B51]) along with the structures of Na~v~PaS ([@B251]), electric eel ([@B319]) and human Na~v~1.4 channels ([@B205]) have provided new structural insight into the mechanism of fast inactivation in Na~V~ channels ([**Figure 6D**](#f6){ref-type="fig"}). In the resting state R5 on S4~IV~ forms an electrostatic bridge with the α1 helix of the C-terminal cytoplasmic domain (CTD), together with K7 and R8 on the S4--S5 linker. The CTD in turn binds the III/IV linker, sequestering the IFM motif ([**Figure 6D**](#f6){ref-type="fig"}, left plot). VSD~IV~ activation releases the connection between the CTD and the III/IV linker (middle and right plots in [**Figure 6D**](#f6){ref-type="fig"}), permitting the IFM motif to bind to a hydrophobic pocket formed by the S4--S5 linkers and S6 helices of repeats III and IV, along with S5~IV~ ([**Figures 6C, E**](#f6){ref-type="fig"}). The insertion of the IFM motif into this pocket causes a twisting in the S6 helices that closes the gate ([@B319]; [@B205]).

![Structural mechanisms of Na~V~ channel inactivation. **(A)** Na~V~ channels transition from an activated open state to a non-conducting inactivated state after depolarization. Inactivation is induced by binding of a C-terminal motif (yellow) to the cytosolic side of the channel leading to pore closure. The cell membrane is indicated with a gray rectangle, with the extracellular (EXT) and intracellular space (INT) labeled. **(B)** Closed state model of SCN5A ([@B137]) highlighting structural elements involved in fast inactivation. The III-IV linker (cyan) connecting S6~III~ (blue) with VSD~IV~ (green) contains the IFM motif (yellow spheres) which is the key structural element responsible for inactivation. The position of the III-IV linker is constrained by the CTD following S6~IV~. **(C)** Comparison of the SCN5A model in **(B)** with a cryo-EM structural model of rat SCN5A (PDB: 6UZ3)([@B116]) in a putative inactivated state viewed from the intracellular side. The III-IV linker undergoes a large shift in the SCN5A structure and the IFM motif is docked into a pocket surrounded by the S4--S5 linkers and S6 helices of repeats III and IV. **(D)** Structural states and transitions proposed to be involved in fast inactivation in Na~V~ channels. Left: Structure of a chimeric Na~V~1.7--Na~V~PaS channel ([@B51]) (PDB: 6NT3) with S4~IV~ in a "down" position and an IFM-like motif unbound. Basic sites R5--R8 bridge to conserved acidic residues on the CTD which facilitates binding of the III-IV linker to S6~IV~. Middle: Structure of a chimeric Na~V~1.7--Na~V~PaS channel ([@B51]) (PDB: 6NT4) with S4~IV~ in a 'up' position and an IFM-like motif unbound. The electrostatic bridge between S4~IV~ and the CTD is broken possibly increasing the positional dynamics of the CTD and III-IV linker. Right: Structure of SCN5A (PDB: 6UZ3) ([@B116]) with S4~IV~ in an 'up' position and the IFM motif plugged into the cytosolic cavity between repeats III and IV. Note, that the CTD is missing in the cryo-EM structure. **(E)** IFM binding pocket residues on S4--S5~III~, S4--S5~IV~, S6~III~, and S6~IV~ of SCN5A (PDB: 6UZ3) ([@B116]). The S6~IV~ helix backbone in the front is not shown for clarity. Residues that are important for fast inactivation and those found in various types of myotonia ([@B205]) are labeled magenta and orange, respectively.](fphar-11-00550-g006){#f6}

Regulation of Channel Gating by Intracellular Domains And Auxiliary Molecules {#s3}
=============================================================================

The function of these cardiac channels is tightly regulated to produce currents that faithfully give rise to the cardiac action potential under a host of physiological conditions and prevent early or delayed contractility. We focus here on regulation through the channel cytoplasmic domains as well as regulation by auxiliary (beta) subunits and lipids. Channels are regulated through other mechanisms such as phosphorylation, but are not covered in this review.

Regulation Involving Cytoplasmic Domains {#s3_1}
----------------------------------------

### KCNQ1 {#s3_1_1}

The C-terminal cytoplasmic domain (CTD) of KCNQ1 contains four alpha helices in lieu of the T1 tetramerization domain common to K~v~ channels outside the KCNQ family ([@B87]). The proximal HA and HB helices form an antiparallel bundle with an IQ motif in HA and a 1-5-10 motif in HB that together enable calmodulin (CaM) binding ([@B325]). When bound, CaM prevents channel inactivation in KCNQ1, but inhibits the opening of other KCNQ family members (KCNQ2--KCNQ5) ([@B42]). While the N-lobe of CaM may be constitutively bound to both calcium and the proximal HA and HB helices ([@B77]; [@B20]), the C-lobe of CaM binds calcium only at higher concentrations ([@B20]). Calcium binding by the C-lobe induces a conformational change in CaM, facilitating KCNQ1 opening ([@B20]; [@B42]). The C-lobe interacts with HA and with a loop in the S2--S3 linker ([@B263]). This feature may contribute to the unique mode of CaM modulation of KCNQ1.

The distal helices HC and HD of KCNQ1 form a self-assembling intersubunit coiled-coil motif that promotes channel tetramerization ([@B325]; [@B106]; [@B263]). The distal coiled-coil domain is not only essential for channel tetramerization, but also for subunit specificity, permitting the exclusive formation of KCNQ1 homotetramers ([@B238]; [@B87]; [@B232]). In contrast, other KCNQ family proteins form heteromers ([@B238]). Swapping the coiled-coil domain of KCNQ1 with that of KCNQ3 allows the resulting chimera to co-assemble with other KCNQ isoforms and generate channels with altered gating properties ([@B238]; [@B239]). Residues conferring specific KCNQ1 homotetramer formation have been identified in the HD helix ([@B239]; [@B304]). Key interactions involve both the hydrophobic core of the assembly and exterior electrostatic interactions, with a number of the residues involved subject to LQTS-associated mutations ([@B106]; [@B304]).

### hERG {#s3_1_2}

hERG channels contain an N-terminal Per-ARNT-Sim (PAS) domain, which is also present in the N-terminus of many signaling proteins ([@B94]). An additional C-terminal cyclic nucleotide-binding homology domain (CNBHD) similar to cytoplasmic domains in hyperpolarization-sensitive cyclic nucleotide-gated channels is present, but without ligand-binding properties ([@B52]). The PAS and the CNBHD appear to be critical for modulating the kinetics of slow deactivation in hERG ([@B86]). Furthermore, slow deactivation is dependent on the direct interaction of these domains, particularly between R56 of the PAS and D803 of the CNBHD and between N12 of the N-terminal Cap (N-Cap) and E788 of the CNBHD ([@B199]; [@B139]). Interactions between the N-Cap and PAS domains with the C-linker also appear to be important for deactivation ([@B86]; [@B199]), and the extreme N-terminus is likely essential, possibly interacting with the VSD through a patch of positively-charged residues in the N-Cap tail ([@B192]). Indeed, the hERG cryo-EM structure corroborates the positioning of the N-Cap tail relative to the VSD ([@B294]). The N-Cap tail may even be constitutively bound to the VSD ([@B182]; [@B56]), implying that slow deactivation could involve movement of the PAS toward the plasma membrane to alter this interaction ([@B15]).

### SCN5A {#s3_1_3}

Multiple structures of the SCN5A CTD in complex with regulatory factors ([@B299]; [@B73]; [@B74]) have been determined, helping to elucidate how CaM ([@B117]) and fibroblast growth factor-homologous factors (FHFs), specifically FGF13, modulate inactivation ([@B156]; [@B299]; [@B191]; [@B322]). CaM binds the CTD in a calcium-dependent manner ([@B131]; [@B105]; [@B117]; [@B281]), altering inactivation kinetics ([@B318]; [@B117]) and promoting recovery from inactivation ([@B117]). In the absence of FHF, the C-lobe of apo-CaM binds to the IQ motif located in an extended helix on the CTD, while the N-lobe binds to the preceding EF hand-like domain (EFL) ([@B73]). With increasing intracellular calcium, holo-CaM has stronger affinity for the SCN5A III/IV linker ([@B117]) and the N-lobe disassociates from the EFL ([@B74]). These calcium-dependent interactions with the III/IV linker may facilitate CaM modulation of inactivation ([@B105]; [@B117]). FGF13 slows both inactivation onset and inactivation recovery in SCN5A ([@B322]), opposing CaM modulation. Importantly, binding of FGF13 to the SCN5A EFL ([@B299]) prevents binding of the apo-CaM N-lobe to the same domain ([@B299]). The EFL itself also adopts different orientations when bound to FGF13 ([@B299]) or CaM ([@B73]). Because the EFL also binds to the III/IV linker containing the IFM inactivation motif ([@B251]; [@B51]), EFL conformational changes upon binding of CaM or FGF13 may contribute to inactivation modulation by these proteins.

SCN5A also contains two cytoplasmic loops linking repeats I and II and repeats II and III, respectively. Unlike the III/IV linker, these loops are around 200 residues long ([@B205]) and likely disordered, based on the absence of these loops in cryo-EM structures. However, important regulatory events such as phosphorylation ([@B169]; [@B113]) and cofactor binding ([@B308]) that modulate channel properties have been identified in these loops.

Auxiliary Beta Subunits {#s3_2}
-----------------------

### KCNQ1 {#s3_2_1}

KCNQ1 co-assembles with a family of single span membrane proteins (KCNE1--5) ([@B3]), and this interaction appears to be tissue--specific. In the heart, KCNQ1 is complexed with KCNE1, and the KCNQ1-KCNE1 channel exhibits greater single-channel conductance, opening at more positive potentials, and delayed activation compared to KCNQ1 alone ([@B13]; [@B234]). This heteromultimeric channel also exhibits altered Rb^+^/K^+^ selectivity ([@B221]) and loss of inactivation ([@B220]; [@B221]). These properties are essential for the generation of the slow delayed rectifier current (I~Ks~) in repolarizing cardiomyocytes. In gastric parietal cells, KCNQ1 co-assembles with KCNE2 to create constitutive K^+^ currents essential for gastric acid secretion ([@B92]; [@B230]). In intestinal epithelial cells KCNQ1 complexes with KCNE3 to allow K^+^ recycling for trans-epithelial chloride ion secretion ([@B218]). In contrast to KCNE1, KCNE2 and KCNE3 render KCNQ1 constitutively open ([@B237]; [@B274]).

Due to the critical role of the KCNQ1-KCNE1 channel in the cardiac action potential, many research groups have probed the structural interaction between these proteins ([@B267]; [@B314]; [@B50]; [@B262]; [@B298]; [@B40]; [@B148]). Combined results indicate that the transmembrane helix of KCNE1 binds in the cleft between neighboring KCNQ1 subunits and interacts with both the VSD and PD. These binding sites overlap the binding cleft of KCNE3 ([@B264]), indicating that KCNE1 may bind to the same site ([**Figure 7A**](#f7){ref-type="fig"}). In the human KCNQ1-KCNE3 cryo-EM structure ([@B264]) and an earlier Rosetta model of the complex ([@B136]), this cleft is formed by three KCNQ1 subunits ([**Figure 7B**](#f7){ref-type="fig"}). KCNE3 contacts the cytoplasmic half of S5 in one subunit, the extracellular side of S6 in a second one, and along the entire length of S1 and the cytoplasmic side of S4 in a third subunit. Importantly, KCNE1 and KCNE3 produce KCNQ1 currents with different voltage dependencies and gating kinetics ([**Figure 7C**](#f7){ref-type="fig"}). Given the possibility of a common binding cleft, differential modulation of KCNQ1 by KCNE1 and KCNE3 may involve different sidechain interactions within this cleft.

![Binding sites of KCNE proteins on the KCNQ1 channel. **(A)** Left: Mapping of putative KCNE binding sites onto the human KCNQ1 structure (PDB: 6V00) ([@B264]). The position of residues identified to interact with KCNE1 (purple) are indicated by spheres. Right: Cryo-EM structure of human KCNQ1 with CaM and KCNE3 (PDB: 6v00)([@B264]). **(B)** KCNQ1/KCNE3 interaction sites. Left: 6V00. Right: KCNQ1/KCNE3 Rosetta model ([@B136]). Interactions sites were calculated with the InterResidues Python script in PYMOL (The PyMOL Molecular Graphics System, Version 2.2 Schrödinger, LLC.). Interaction positions indicated with sticks. **(C)** Example current traces of KCNQ1 alone or with KCNE proteins. Adapted with permission from ([@B284]).](fphar-11-00550-g007){#f7}

Mutations in the KCNE1 transmembrane helix, particularly at F57, T58, and L59 ([@B176]; [@B177]), alter the ability of this subunit to modulate the function of KCNQ1. The effect of this 'activation' triplet on KCNQ1 gating is altered by mutations at residues S338, F339, F340, and A341 in S6 ([@B178]; [@B208]; [@B262]; [@B148]), suggesting a functional link between these residues. However, modeling studies fail to indicate direct contact between the activation triplet on KCNE1 and these S6 sites ([@B124]; [@B80]; [@B315]), suggesting that the functional coupling may be mediated allosterically. Interestingly, KCNE1 also affects S4 movement ([@B228]; [@B309]; [@B195]) and shifts VSD voltage-dependence of activation to more negative voltages ([@B203]; [@B231]; [@B17]). A model of KCNE1 regulation has recently been proposed, in which KCNE1 alters VSD-PD coupling interactions to suppress the IO state and modulate the AO state ([@B327]). This model accounts for many of the observed effects of KCNE1 on KCNQ1, including KCNE1-induced inhibition of inactivation. However, this model is not structurally elaborated.

### hERG {#s3_2_2}

Previous studies indicate that KCNE1 ([@B173]) and KCNE2 ([@B1]) can interact with and modulate hERG function. However, whether this interaction occurs under physiological conditions is debated ([@B302]; [@B9]; [@B2]). Although KCNE1 and KCNE2 alter hERG gating kinetics *in vivo* ([@B173]; [@B171]), co-expression of KCNE2 with hERG *in vitro* does not reproduce the native I~Kr~ current ([@B302]). This suggests that KCNE1 and KCNE2 may not be essential for hERG channel function or that additional factors are required for KCNE-hERG interaction in cardiac cells. The latter possibility is supported by the observation that mutations in KCNE2 may predispose patients to drug-induced LQTS ([@B1]; [@B250]). As hERG is particularly drug-sensitive, this finding suggests that hERG may, in fact, be modulated by KCNEs in native tissue. Additionally, a T10M mutation in KCNE2 causes arrhythmia induced by auditory stimulation, a known trigger of LQT2, ([@B83]). Further studies are needed to resolve these conflicting results and clarify the role of KCNE proteins in regulation of hERG function.

### SCN5A {#s3_2_3}

In humans there are five Na~V~-β-subunit protein isoforms encoded by four genes, SCN1B-SCN4B (β1 to β4) ([@B58]; [@B201]). All are expressed in the heart and have been shown to associate with SCN5A in heterologous conditions ([@B167]; [@B59]; [@B168]; [@B175]; [@B301]; [@B283]). β1 to β4 are single-span transmembrane proteins containing an extracellular N-terminal immunoglobulin (Ig) domain, while β1B, a splice variant of SCN1B, lacks the transmembrane domain ([@B32]). Generally, β-subunits modulate the biophysical properties and cell surface expression of Na~V~ channels in heterologous cells ([@B35]). β1 and β3 interact non-covalently with Na~V~ channels ([@B174]), while β2 and β4 are covalently bound through cysteine bonds between the extracellular Ig domain and channel pore loops. However, modulation of SCN5A by β-subunits has been difficult to assess. Varying effects of β1 ([@B222]; [@B59]; [@B14]; [@B335]) as well as β3 ([@B107]; [@B283]; [@B297]) on SCN5A have been reported. The rat SCN5A structure provides a potential explanation for this difficulty, as SCN5A is missing a cysteine residue critical for covalent interaction with β2, and contains a glycosylation site that may sterically occlude β1 interaction ([@B116]). SCN5A may not bind tightly with any β-subunit. Nevertheless, the potential importance of β-subunits in SCN5A modulation has been suggested by arrhythmia-associated mutations in all four β-subunit genes, including mutations causing Brugada syndrome ([@B300]; [@B107]; [@B108]), LQT3 ([@B175]; [@B227]), and atrial fibrillation ([@B301]; [@B202]). However, a recent review of genetic evidence supporting these associations has disputed the clinical validity of β subunits as monogenic causes of arrhythmia syndromes ([@B100]; [@B5]).

SCN5A subcellular localization also contributes importantly to channel regulation. SCN5A channels in cardiac tissue are localized at the lateral membranes and at the anchoring junction between cardiomyocytes (the intercalated disc). These expression patterns give rise to distinct sets of protein-protein interactions and biophysical properties ([@B153]; [@B255]). At the lateral membrane SCN5A interacts with the dystrophin/syntrophin multicomplex, but at the intercalated disc SCN5A interacts with ankyrin-G ([@B145]; [@B181]), which links the channel to cytoskeletal proteins such as actin and the desmosomal protein plakophilin-2 ([@B166]). Intriguingly, the functional properties of SCN5A channels between these two pools also differ: SCN5A at the lateral membrane has smaller current amplitude, distinct voltage-dependence, and slower recovery from inactivation as compared to channels in the intercalated disc ([@B153]). The functional implications of these differences are not yet clear and remain an active area of study.

Lipid Molecules {#s3_3}
---------------

### KCNQ1 {#s3_3_1}

KCNQ1 and other KCNQ channels are dependent on phosphatidyl-4,5-bisphosphate (PIP~2~) for function ([@B161]; [@B326]; [@B268]), and are inhibited upon stimulation of G~q~- and G~11~-protein coupled receptors, which trigger phospholipase C-catalyzed PIP~2~ hydrolysis ([@B248]; [@B161]; [@B329]) ([**Figure 8B**](#f8){ref-type="fig"}). Growing evidence suggests that PIP~2~ acts as a coupling element for KCNQ1, enhancing weak allosteric interactions between the VSD and PD ([@B289]; [@B326]; [@B127]; [@B55]). Structure-function studies, confirmed by the human KCNQ1/PIP~2~ structure, localize PIP~2~ binding to the cleft between neighboring channel subunits, with interactions involving mostly positively-charged residues in the S2--S3 linker, S4--S5 linker, and S6~C~ ([**Figure 8A**](#f8){ref-type="fig"}) ([@B273]; [@B326]; [@B63]; [@B45]; [@B264]). This binding site seems well-suited to modulate coupling of VSD movement to the activation gate. Questions remain regarding the mechanism of PIP~2~ regulation of VSD-PD coupling, PIP~2~:KCNQ1 stoichiometry, and binding site differences between the activated and resting states.

![Binding sites of lipids on the KCNQ1 channel. **(A)** Mapping of positions that have been implicated in the regulation of KCNQ1 by PUFAs (cyan) and PIP~2~ (yellow) onto the PIP~2~-bound KCNQ1 structure (6V01) ([@B264]). Inset: the PIP~2~ cryo-EM binding site. **(B)** Left: Effect of the PUFA head group charge on the voltage dependence of KCNQ1 conductance (inspired from results in [@B151]). Right: PIP~2~ depletion reduces KCNQ1 ionic currents due to decreased VSD-PD coupling.](fphar-11-00550-g008){#f8}

PIP~2~ also binds to the CTD at a site shared with CaM ([@B276]). These two regulators may competitively regulate KCNQ1 at this site ([@B275]). Indeed, in the human KCNQ1 cryo-EM structure, CaM exhibits a nearly 180° rotation when PIP~2~ is bound, losing contact with the S2--S3 linker ([@B264]). Additionally, S6 and HA in KCNQ1 form a single helix in the open channel. These structural shifts point to an interplay between PIP~2~ and CaM, but does not clarify the nature of this interaction, as no PIP~2~ density was seen at the CTD binding site in the cryo-EM structure. The details of the coordination between CaM and PIP~2~, and its role in channel function, remain to be elucidated.

Polyunsaturated fatty acids (PUFAs) also modulate KCNQ1 function ([@B268]). While PUFAs generally inhibit ion channel current ([@B28]), the KCNQ1-KCNE1 channel is a notable exception. The I~Ks~ current is enhanced by docosahexaenoic acid (DHA) and, to a lesser extent, oleic acid ([@B60]) by shifting the conductance-vs-voltage curve (GV) to more negative voltages. Interestingly, the charge of the head group determines the direction of the (GV) shift ([**Figure 8B**](#f8){ref-type="fig"}): negatively-charged DHA causes a negative shift, a neutral head group has no effect, and a positively-charged one shifts the (GV) curve to positive potentials, reducing channel function ([@B151]). Negative head group charge and a polyunsaturated acyl chain appear to be required for channel activation. The PUFA binding site in KCNQ1 appears to involve residues in the extracellular S3--S4 loop, R1 and R2 on S4, and the PD ([**Figure 8A**](#f8){ref-type="fig"}), as mutations in these regions either reduce the PUFA effect or completely abolish the (GV) shift ([@B151]; [@B152]).

### hERG {#s3_3_2}

As with KCNQ1, the function of hERG is upregulated by PIP~2~ by means of increased current amplitude, a hyperpolarizing shift in voltage-dependence of activation, as well as faster activation and slower inactivation rates ([@B23]). Stimulation of G~αq~-protein coupled receptors also suppresses the I~Kr~ current through PIP~2~ depletion ([@B23]; [@B24]). Binding of PIP~2~ to hERG likely localizes to a cluster of basic residues (R883--Q900) C-terminal to the CNBHD, as substitution of these residues to neutral or negatively-charged amino acids prevented PIP~2~ effects on hERG function and abolished PIP~2~ binding ([@B24]). Unfortunately, these residues are not resolved in the available hERG structure ([@B294]).

### SCN5A {#s3_3_3}

In contrast to KCNQ1, PUFAs such as eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), linoleic acid (LA), and α-linolenic acid (ALA) suppress I~Na~ current in a concentration-dependent manner by shifting the voltage dependence of I~Na~ inactivation to more hyperpolarized potentials ([@B122]; [@B123]; [@B143]). EPA also accelerates the transition from the resting state to the inactivated state and slows recovery from inactivation ([@B312]; [@B114]). However, the effect was reduced by β1 subunit expression (Xiao et al, 2000). Furthermore, N406K renders SCN5A less sensitive to inhibition by EPA, an effect strengthened by β1 subunit expression ([@B313]). The structural basis for PUFA binding and modulation is not well understood.

Channel Dysfunction in Congenital Long QT Syndrome {#s4}
==================================================

Alterations in the action potential disturb impulse propagation and cause reentry ([@B133]), whereby the impulse re-stimulates the heart tissue that generated it. Reentry promotes cardiac arrhythmias and predisposes to sudden unexplained death ([@B256]). LQTS is a prevalent cause of such events, with an estimated population prevalence of approximately 1:2500 ([@B241]).

LQTS is characterized by a prolonged rate-corrected QT interval in patient electrocardiograms (ECGs), indicative of impaired repolarization ([@B242]). In a large proportion of cases, QT interval prolongation is the result of either a loss-of-function in KCNQ1 or hERG, or a gain-of-function in the SCN5A channel ([@B187]; [@B242]; [@B62]; [@B256]). Mutations in these genes confer distinct subtypes of LQTS (denoted LQT1--3, respectively), each with unique ECG features, risk factors, arrhythmia triggers, and responsiveness to β-adrenergic receptor blockers, the most common LQTS treatment ([@B4]; [@B187]; [@B256]; [@B293]). Below, the function of each ion channel in the cardiac action potential is discussed, along with how each can cause action potential dysfunction in LQTS.

Channel Function in the Cardiac Action Potential and Dysfunction in LQTS {#s4_1}
------------------------------------------------------------------------

### KCNQ1 {#s4_1_1}

In complex with KCNE1, KCNQ1 conducts I~Ks~, which helps shape the plateau and repolarization phases of the action potential, in part by counteracting calcium influx ([@B256]). Due to slow activation, the KCNQ1-KCNE1 channel is only slightly open during the plateau phase, with I~Ks~ increasing slowly in a nearly linear fashion ([**Figure 7C**](#f7){ref-type="fig"}) until the repolarization phase is reached and the channel becomes fully activated ([**Figures 1B, C**](#f1){ref-type="fig"}) ([@B187]). KCNQ1-KCNE1 channels do not inactivate ([@B220]), conducting current throughout activation and deactivation. The channel slowly deactivates, shaping the tail of the repolarization phase and mediating return to the resting potential ([@B187]; [@B76]; [@B256]). Thus, loss-of-function in KCNQ1 prolongs repolarization primarily by preventing completion of the repolarization phase, broadening the tail of the T-wave ([**Figure 1A**](#f1){ref-type="fig"}) and causing type 1 LQTS (LQT1). ([@B4]; [@B271]; [@B256]; [@B293]). The effects of a KCNQ1 mutation are exacerbated upon sympathetic activation of β-adrenergic receptors due to I~Ks~ potentiation, while resting heart rates show few perturbations ([@B253]). The QT interval is unable to shorten in response to this stimulation, making physical exertion accompanied by heightened sympathetic nervous system activity a prevalent LQT1 trigger ([@B242]; [@B27]).

### hERG {#s4_1_2}

hERG makes up the other primary inward rectifier current I~Kr~, which acts in both the plateau and the repolarization phase ([**Figures 1B, C**](#f1){ref-type="fig"}) ([@B187]; [@B256]). As the channel activates, rapid entry into and out of inactivation (due to SF fluctuations) creates a persistent current through the plateau phase until slow deactivation, regulated by the PAS and CNBHD domains, closes the channel during the repolarization phase. While both hERG and KCNQ1 are conductive during the plateau and repolarization phases, hERG has a higher unitary conductance than KCNQ1 in both phases ([@B187]; [@B76]). The resulting I~Kr~ current thus supplies a greater proportion of the overall I~K~ current ([@B48]), with loss-of-function in hERG (LQT2) correlating with a lower T-wave amplitude in contrast to the normal T-wave amplitude associated with LQT1. Additionally, LQT2 is often triggered at rest ([@B256]), consistent with the greater hERG contribution to I~K~. However, while I~Kr~ is usually more prominent ([@B48]), the relative density of I~Kr~ and I~Ks~ vary by ventricular cell type ([@B155]; [@B290]).

### SCN5A {#s4_1_3}

SCN5A produces the I~Na~ current that shapes the initial upstroke of the cardiac action potential ([@B256]), initiating depolarization. SCN5A is rapidly activated through asynchronous motion of the VSD's in repeats I-III coupled to pore opening, then quickly inactivates through interaction of the IFM motif with the channel, resulting in a brief inward spike of sodium current that depolarizes the cell ([@B78]) ([**Figures 1B, C**](#f1){ref-type="fig"}). Unlike KCNQ1 and hERG, LQT3 is conferred by SCN5A gain-of-function mutations that cause a "leaky" inward sodium current ([@B305]; [@B256]). The functional I~Kr~ and I~Ks~ outward currents are unable to compensate for the persistent inward I~Na~ current, prolonging entry into and completion of the repolarization phase and giving rise to LQT3. As in LQT2, LQT3-related arrhythmias occur most often at rest, rather than in response to stress or exercise ([@B242]). It should be noted that while loss-of-function mutations for SCN5A are not relevant to LQTS, they are prevalent in other channelopathies, particularly Brugada syndrome ([@B305]; [@B256]).

Molecular Mechanisms of LQTS {#s4_2}
----------------------------

Mutations in KCNQ1, hERG, and SCN5A can lead to LQTS by perturbing channel function through distinct molecular mechanisms. Structural studies of these channels can help tease apart these molecular mechanisms for a more detailed understanding of LQTS. We have mapped LQTS mutations identified as pathogenic according to ClinVar ([@B90]) and HGMD ([@B261]) databases onto the human KCNQ1 ([@B264]) and hERG structures ([@B294]), as well as a recent model of SCN5A ([@B137]) and the rat SCN5A homolog ([@B116]) ([**Figures 9**](#f9){ref-type="fig"}--[**11**](#f11){ref-type="fig"}). The list of curated mutations is found in [**Table 1**](#T1){ref-type="table"}: 261 mutations in KCNQ1, 320 mutations in hERG, and 122 mutations in SCN5A. Examination of these mutation sites provides some insight into the channel mechanisms that may be commonly disrupted in LQT1--3.

![Human KCNQ1 structure with deleterious mutation sites indicated. **(A)** Full KCNQ1 structure (PDB: 6UZZ) ([@B264]). Yellow sites denote locations of a single deleterious mutation, while red indicates sites with multiple mutations identified. Spheres indicate C-alpha positions of mutation sites. Subunit with LQT1 mutations sites mapped is colored green. Inset: of SF and pore helix. **(B)** KCNQ1 VSD. **(C)** S4--S5 linker (S4--S5) interaction site close-up. One subunit is colored green and the others in gray, for clarity. The PAG motif (PAG) is indicated with sticks. **(D)** Top: HC coiled-coil domain. Bottom: HD coiled-coil domain (PDB: 3BJ4) ([@B304]). Residue side chains are indicated with sticks.](fphar-11-00550-g009){#f9}

![hERG structure with deleterious mutation sites indicated. **(A)** Full hERG structure (PDB: 5VA1) ([@B294]). Yellow sites denote locations of a single deleterious mutation, while red indicates sites with multiple mutations identified. Spheres indicate C-alpha positions of mutation sites. Subunit with LQT2 mutations sites mapped is colored green. Inset: close-up of SF and pore helix. **(B)** hERG VSD. **(C)**. Close-up of the S1/S5 interface. Residues at the interface are indicated with sticks **(D)** N-terminal PAS (dark gray) and C-terminal CNBHD (light gray) domain interface, cartoon representation with surface representation overlay. One subunit is green and the other gray, for clarity.](fphar-11-00550-g010){#f10}

![Rat SCN5A structure with deleterious mutation sites indicated. **(A)** Full SCN5A structure (PDB: 6UZ3) ([@B116]). Yellow sites denote locations of a single deleterious mutation, while red indicates sites with multiple mutations identified. Spheres indicate C-alpha positions of mutation sites. Side views of individual repeats are shown with 90° rotations between panels. In each panel, one repeat is colored green and LQT3 mutation sites for that repeat are mapped. **(B)** C-terminal domain with bound III/IV linker (human SCN5A model: \[([@B134])\]. **(C)** Putative inactivation gate. IFM motif is indicated with sticks. **(D)** SCN5A constriction site. S6 helices are shown at full opacity, with the IFM motif indicated with sticks.](fphar-11-00550-g011){#f11}

###### 

LQTS mutations in KCNQ1, hERG, and SCN5A.

  KCNQ1    hERG            SCN5A                                                                                                               
  -------- --------------- --------- --------------- --------- --------------- --------- --------------- ---------- --------------- ---------- ---------------
  A58P\*   HGMD            T311I     HGMD            G6R       HGMD            G572R     ClinVar, HGMD   G9V\*      HGMD            G1329S     HGMD
  S66F\*   HGMD            T312S     HGMD            G6V       HGMD            G572S     HGMD            R18W\*     HGMD            A1330P     HGMD
  T96R\*   HGMD            T312I     ClinVar, HGMD   T13N      HGMD            G572V     HGMD            A29V\*     HGMD            A1330T     HGMD
  T104I    HGMD            I313M     HGMD            D16A      HGMD            M574V     HGMD            E30G\*     HGMD            P1332L     HGMD
  Q107H    HGMD            G314A     HGMD            R20G      HGMD            E575G     HGMD            P52S\*     HGMD            S1333Y     HGMD
  R109L    HGMD            G314D     HGMD            F22S      HGMD            E575K     HGMD            R53Q\*     HGMD            L1338V     HGMD
  Y111C    ClinVar, HGMD   G314C     HGMD            F22Y      HGMD            R582C\*   ClinVar         R104G\*    HGMD            A1357V     HGMD
  L114P    HGMD            G314R     ClinVar, HGMD   S26I      HGMD            G584S     HGMD            A110T\*    HGMD            G1391R     HGMD
  E115G    HGMD            G314S     ClinVar, HGMD   R27P      HGMD            G584V     HGMD            V113I\*    HGMD            A1428S     HGMD
  P117L    ClinVar, HGMD   Y315N     HGMD            K28E      HGMD            W585C     HGMD            S115G\*    HGMD            S1458Y     ClinVar, HGMD
  C122Y    ClinVar, HGMD   Y315C     HGMD            F29L      HGMD            L586M     HGMD            I176M      HGMD            N1472S     HGMD
  Y125D    HGMD            Y315H     HGMD            F29S      HGMD            N588D     HGMD            A185T      HGMD            F1473C     HGMD
  F127L    HGMD            Y315F     HGMD            I31S      HGMD            G590V     HGMD            I239V      HGMD            F1473S     HGMD
  L131P    HGMD            Y315S     HGMD            I31T      ClinVar, HGMD   I593T     ClinVar         V240M      HGMD            Q1476R     HGMD
  I132L    HGMD            G316E     HGMD            A32T      HGMD            I593K     ClinVar, HGMD   Q245K      HGMD            G1481E     HGMD
  V133I    HGMD            G316V     HGMD            N33T      HGMD            I593R     ClinVar, HGMD   V258A      HGMD            T1488R     HGMD
  L134P    ClinVar, HGMD   G316R     ClinVar, HGMD   R35W      HGMD            I593V     HGMD            R340Q      HGMD            Y1495S     HGMD
  C136F    HGMD            D317N     ClinVar, HGMD   V41F      HGMD            G594D     HGMD            A385T      HGMD            K1505N     HGMD
  L137F    ClinVar, HGMD   D317G     HGMD            V41A      HGMD            K595N     HGMD            I397T      HGMD            T1544P     HGMD
  S140R    HGMD            D317Y     HGMD            I42N      HGMD            K595E     HGMD            L404Q      HGMD            L1560F     HGMD
  E146G    HGMD            K318N     ClinVar, HGMD   Y43C      HGMD            P596H     ClinVar, HGMD   N406K      HGMD            I1593M     HGMD
  E146K    HGMD            P320A     HGMD            Y43D      HGMD            P596A     ClinVar, HGMD   L409P      HGMD            F1594S     HGMD
  A150G    HGMD            T322K     HGMD            C44F      HGMD            P596R     HGMD            L409V      HGMD            V1597M     HGMD
  T153M    HGMD            T322A     ClinVar, HGMD   C44W      HGMD            P596L     HGMD            V411M      ClinVar, HGMD   S1609W     HGMD
  F157C    HGMD            T322M     ClinVar, HGMD   C44Y      HGMD            P596S     HGMD            A413E      HGMD            R1623Q     ClinVar, HGMD
  E160K    HGMD            G325R     ClinVar, HGMD   N45D      HGMD            P596T     HGMD            R504T\*    HGMD            R1623L     HGMD
  E160V    HGMD            G325E     HGMD            N45S      HGMD            Y597C     HGMD            M506K\*    HGMD            R1626P     HGMD
  G168R    ClinVar, HGMD   G325W     HGMD            N45Y      HGMD            G604D     HGMD            F530V\*    HGMD            R1644H     ClinVar, HGMD
  T169R    HGMD            S338F     HGMD            D46Y      HGMD            G604S     ClinVar, HGMD   D536H\*    HGMD            L1646R     HGMD
  T169K    HGMD            F339S     HGMD            G47D      HGMD            P605S     HGMD            R569W\*    HGMD            L1650F     HGMD
  E170G    HGMD            F339V     HGMD            G47V      HGMD            S606F     HGMD            Q573E\*    HGMD            M1652R     HGMD
  V173D    HGMD            F340L     HGMD            C49Y      HGMD            S606P     HGMD            G579R\*    HGMD            M1652T     HGMD
  R174C    ClinVar, HGMD   A341G     HGMD            G53R      HGMD            D609G     HGMD            P637L\*    HGMD            P1725L     HGMD
  R174H    ClinVar, HGMD   A341V     ClinVar, HGMD   G53D      HGMD            D609H     HGMD            E654K\*    HGMD            A1746T     HGMD
  W176R    HGMD            A341E     ClinVar, HGMD   G53S      HGMD            D609N     ClinVar, HGMD   A665S\*    HGMD            I1758V     HGMD
  A178T    HGMD            L342F     HGMD            G53V      HGMD            D609Y     HGMD            R689C\*    HGMD            L1761H     HGMD
  A178P    ClinVar, HGMD   P343R     HGMD            Y54H      HGMD            K610N     HGMD            G709V\*    HGMD            L1761F     HGMD
  K183R    HGMD            P343L     HGMD            S55L      ClinVar, HGMD   Y611D     HGMD            T731I      HGMD            V1763L     HGMD
  K183M    HGMD            P343S     HGMD            R56Q      HGMD            Y611H     ClinVar, HGMD   Q750R      HGMD            V1763M     ClinVar, HGMD
  Y184C    HGMD            A344E     HGMD            A57P      HGMD            V612L     HGMD            Q779K      HGMD            M1766L     ClinVar, HGMD
  Y184H    HGMD            A344V     ClinVar, HGMD   E58A      HGMD            V612M     HGMD            R800L\*    HGMD            M1766V     HGMD
  Y184S    HGMD            G345R     ClinVar, HGMD   E58D      HGMD            T613A     HGMD            R808P      HGMD            Y1767C     HGMD
  G186R    HGMD            G345E     ClinVar, HGMD   E58G      ClinVar, HGMD   T613K     HGMD            F816Y      HGMD            I1768V     ClinVar, HGMD
  G189A    HGMD            G345A     HGMD            E58K      HGMD            T613M     ClinVar, HGMD   L828V      HGMD            L1772V     HGMD
  G189E    HGMD            G345V     HGMD            Q61R      HGMD            A614V     ClinVar, HGMD   N834D      HGMD            N1774D     HGMD
  G189R    ClinVar, HGMD   L347P     HGMD            R62Q      HGMD            L615F     HGMD            G840R      HGMD            E1781G     HGMD
  R190Q    ClinVar, HGMD   S349W     ClinVar, HGMD   C64W      HGMD            Y616C     HGMD            T843A      ClinVar, HGMD   E1784K     HGMD
  R190L    HGMD            S349P     HGMD            C64Y      HGMD            F617L     HGMD            Q912R      HGMD            D1790G     HGMD
  R190W    HGMD            G350R     HGMD            T65P      ClinVar, HGMD   F617V     HGMD            S941N      ClinVar         Y1795C     ClinVar, HGMD
  L191P    HGMD            G350V     HGMD            C66G      HGMD            T618S     HGMD            Q960K\*    HGMD            P1824A     HGMD
  R192P    HGMD            F351L     ClinVar         F68L      HGMD            S620N     HGMD            R975W\*    HGMD            D1839G     HGMD
  F193L    HGMD            F351S     HGMD            L69P      HGMD            S620G     HGMD            C981F\*    HGMD            R1860S     HGMD
  R195P    HGMD            L353P     ClinVar, HGMD   H70R      HGMD            S621R     HGMD            P1021S\*   HGMD            A1870T     HGMD
  K196T    HGMD            K354R     HGMD            H70N      HGMD            S621N     HGMD            D1166N\*   HGMD            R1897W\*   HGMD
  P197S    HGMD            Q357R     HGMD            G71E      HGMD            T623I     HGMD            R1175C\*   HGMD            E1901Q\*   HGMD
  I198V    ClinVar, HGMD   R360M     HGMD            G71R      ClinVar, HGMD   V625A     HGMD            P1177L\*   HGMD            A1949S\*   HGMD
  S199A    HGMD            R360T     HGMD            G71W      HGMD            V625E     HGMD            Y1199S\*   HGMD            E1954K\*   HGMD
  I200N    HGMD            K362R     HGMD            P72L      ClinVar, HGMD   G626A     HGMD            Y1241S     HGMD            Y1977N\*   HGMD
  D202G    ClinVar         H363N     ClinVar, HGMD   P72T      HGMD            G626D     HGMD            I1278N     HGMD            L1988R\*   HGMD
  D202H    HGMD            N365H     HGMD            T74P      HGMD            G626S     HGMD            N1325S     ClinVar, HGMD   R1991Q\*   HGMD
  L203P    HGMD            R366Q     ClinVar         T74R      ClinVar, HGMD   G626V     HGMD            A1326S     ClinVar, HGMD   F2004V\*   HGMD
  I204M    HGMD            R366P     HGMD            A78V      HGMD            F627I     HGMD                                                  
  I204F    HGMD            R366W     HGMD            A78T      HGMD            F627L     HGMD                                                  
  V205M    ClinVar, HGMD   Q367H     HGMD            A80P      HGMD            G628R     HGMD                                                  
  S209F    HGMD            A371T     HGMD            A85P      HGMD            G628D     HGMD                                                  
  K218E    HGMD            A372D     HGMD            A85V      HGMD            G628S     ClinVar, HGMD                                         
  T224M    HGMD            S373P     HGMD            L86R      HGMD            G628V     HGMD                                                  
  S225L    HGMD            W379G     HGMD            L86P      HGMD            G628A     HGMD                                                  
  A226V    HGMD            W379S     HGMD            A89V      HGMD            N629D     ClinVar, HGMD                                         
  I227L    HGMD            R380G     HGMD            E90K      HGMD            N629I     HGMD                                                  
  G229D    HGMD            R380S     HGMD            V94M      HGMD            N629K     HGMD                                                  
  R231C    HGMD            E385K     HGMD            E95G      HGMD            N629S     ClinVar, HGMD                                         
  R231H    ClinVar, HGMD   S389P     HGMD            I96T      HGMD            N629T     HGMD                                                  
  I235N    ClinVar, HGMD   S389Y     HGMD            F98S      HGMD            V630A     HGMD                                                  
  L236R    HGMD            T391I     HGMD            Y99S      HGMD            V630L     HGMD                                                  
  L236P    HGMD            W392R     HGMD            R100Q     ClinVar, HGMD   S631A     HGMD                                                  
  L239P    HGMD            Y395S     ClinVar         R100W     HGMD            P632A     HGMD                                                  
  V241G    HGMD            K422T\*   HGMD            K101E     HGMD            P632S     HGMD                                                  
  D242N    HGMD            T444M\*   HGMD            D102A     HGMD            N633D     HGMD                                                  
  D242Y    HGMD            D446E\*   HGMD            D102H     HGMD            N633I     HGMD                                                  
  R243C    ClinVar, HGMD   H455Y\*   HGMD            D102V     HGMD            N633K     HGMD                                                  
  R243P    ClinVar, HGMD   R511W     HGMD            F106L     HGMD            N633S     HGMD                                                  
  G245V    HGMD            T513S     HGMD            F106Y     HGMD            T634A     HGMD                                                  
  W248C    HGMD            I517T     HGMD            C108R     HGMD            T634I     HGMD                                                  
  L250H    HGMD            M520R     HGMD            C108Y     HGMD            N635D     HGMD                                                  
  L250P    HGMD            Y522S     HGMD            L109R     HGMD            N635I     HGMD                                                  
  L251Q    HGMD            V524G     HGMD            L109P     HGMD            N635K     HGMD                                                  
  L251P    ClinVar, HGMD   A525T     HGMD            D111V     HGMD            E637D     HGMD                                                  
  G252D    HGMD            A525V     HGMD            P114S     HGMD            E637G     HGMD                                                  
  S253C    ClinVar         R539W     ClinVar, HGMD   M124R     HGMD            E637K     ClinVar, HGMD                                         
  V254M    ClinVar, HGMD   E543K     HGMD            M124T     HGMD            K638N     HGMD                                                  
  V254L    HGMD            S546L     HGMD            F129I     HGMD            K638E     HGMD                                                  
  H258N    HGMD            Q547R     HGMD            D219V\*   ClinVar         F640L     ClinVar, HGMD                                         
  H258P    HGMD            G548D     HGMD            P334L\*   ClinVar         F640V     HGMD                                                  
  H258R    ClinVar, HGMD   V554A     HGMD            I400N     HGMD            V644L     HGMD                                                  
  R259C    ClinVar, HGMD   R555C     ClinVar, HGMD   W410S     HGMD            V644F     HGMD                                                  
  R259L    ClinVar, HGMD   R555H     HGMD            L413P     HGMD            M645L     HGMD                                                  
  R259H    HGMD            R555S     HGMD            Y420C     HGMD            M645V     ClinVar, HGMD                                         
  E261Q    HGMD            K557E     HGMD            A422D     HGMD            G648S     HGMD                                                  
  E261K    HGMD            R561G     HGMD            A422T     HGMD            S649P     HGMD                                                  
  E261V    HGMD            R562M     HGMD            P426H     HGMD            M651R     HGMD                                                  
  L262V    HGMD            R562S     HGMD            Y427C     HGMD            S654G     HGMD                                                  
  T265I    ClinVar, HGMD   L563P     HGMD            Y427H     HGMD            F656C     HGMD                                                  
  L266P    HGMD            S566F     HGMD            Y427S     HGMD            F656L     HGMD                                                  
  G269S    ClinVar, HGMD   S566P     HGMD            S428L     HGMD            G657R     HGMD                                                  
  G269D    ClinVar, HGMD   I567F     HGMD            S428P     HGMD            G657C     HGMD                                                  
  G272D    ClinVar         I567S     HGMD            A429P     HGMD            G657S     ClinVar, HGMD                                         
  G272V    HGMD            I567T     HGMD            P451L     HGMD            I662T     HGMD                                                  
  L273F    ClinVar, HGMD   G568A     ClinVar, HGMD   D456Y     HGMD            R685H     HGMD                                                  
  L273R    HGMD            G568R     HGMD            L457P     HGMD            H687Y     HGMD                                                  
  F275S    HGMD            K569E\*   HGMD            D460Y     HGMD            R694H     HGMD                                                  
  S277L    ClinVar, HGMD   S571L\*   HGMD            F463L     HGMD            R696P     HGMD                                                  
  S277P    HGMD            F573L\*   HGMD            D466Y     HGMD            S706C     HGMD                                                  
  S277W    HGMD            R583C\*   HGMD            N470D     ClinVar, HGMD   A715V     HGMD                                                  
  Y278H    HGMD            R583G\*   HGMD            T473N     HGMD            P721L     HGMD                                                  
  Y281C    HGMD            N586D     HGMD            T473P     HGMD            I728F     HGMD                                                  
  L282P    HGMD            N586S     HGMD            T474I     ClinVar, HGMD   R744P     HGMD                                                  
  A283T    HGMD            T587M     ClinVar, HGMD   Y475C     HGMD            R752Q     HGMD                                                  
  A302T    HGMD            G589D     ClinVar, HGMD   E480V     HGMD            R752W     HGMD                                                  
  A302V    HGMD            T587R     HGMD            I489F     HGMD            A753S     HGMD                                                  
  L303P    HGMD            A590T     HGMD            A490P     HGMD            K757N     HGMD                                                  
  W304R    HGMD            R591C     HGMD            A490T     ClinVar, HGMD   D767Y     HGMD                                                  
  W305R    HGMD            R591H     ClinVar, HGMD   H492Y     HGMD            V770A     HGMD                                                  
  W305L    ClinVar, HGMD   R591L     HGMD            Y493C     HGMD            D774Y     HGMD                                                  
  G306R    ClinVar, HGMD   R594Q     HGMD            Y493F     HGMD            G785A     HGMD                                                  
  G306V    HGMD            E596K     HGMD            Y493S     HGMD            G785V     HGMD                                                  
  V308D    HGMD            L602P     HGMD            W497L     HGMD            G785D     HGMD                                                  
  T309R    HGMD            I609N     HGMD            D501N     HGMD            E788D     HGMD                                                  
  T309I    HGMD            D611Y     HGMD            D501G     ClinVar, HGMD   E788K     HGMD                                                  
  V310I    HGMD            G635R\*   HGMD            D501H     HGMD            V795I     HGMD                                                  
  T311A    HGMD                                      G522R     HGMD            G800A     ClinVar                                               
                                                     K525N     HGMD            G800E     HGMD                                                  
                                                     R528P     HGMD            G800W     HGMD                                                  
                                                     R531Q     HGMD            M801I     ClinVar                                               
                                                     R534C     ClinVar, HGMD   D803Y     HGMD                                                  
                                                     R534L     HGMD            F805C     HGMD                                                  
                                                     R537W     HGMD            F805S     ClinVar, HGMD                                         
                                                     L552S     ClinVar, HGMD   G806E     ClinVar, HGMD                                         
                                                     E544A     HGMD            P815L     HGMD                                                  
                                                     A558E     HGMD            G816V     HGMD                                                  
                                                     A558P     ClinVar, HGMD   S818L     HGMD                                                  
                                                     L559H     HGMD            S818P     HGMD                                                  
                                                     A561P     ClinVar, HGMD   S818W     HGMD                                                  
                                                     A561T     ClinVar, HGMD   G820E     HGMD                                                  
                                                     A561V     HGMD            G820R     ClinVar, HGMD                                         
                                                     H562R     HGMD            V822I     ClinVar                                               
                                                     W563C     HGMD            V822L     HGMD                                                  
                                                     W563G     HGMD            V822M     HGMD                                                  
                                                     L564P     HGMD            R823W     HGMD                                                  
                                                     A565T     HGMD            T826I     ClinVar, HGMD                                         
                                                     C566F     HGMD            R835W     HGMD                                                  
                                                     C566S     HGMD            D837N     HGMD                                                  
                                                     W568R     HGMD            D837G     HGMD                                                  
                                                     W568C     HGMD            D837H     HGMD                                                  
                                                     Y569C     HGMD            D837Y     HGMD                                                  
                                                     Y569H     HGMD            V841L     HGMD                                                  
                                                     I571L     HGMD            P846T     HGMD                                                  
                                                     I571M     HGMD            I858T     HGMD                                                  
                                                     G572D     HGMD            N861H     HGMD                                                  
                                                     G572C     HGMD            N861I     ClinVar, HGMD                                         

Curated mutations classified as pathogenic in the ClinVar ([@B90]) and HGMD ([@B261]) databases. Mutations were cross-referenced to remove any mutations with conflicting classifications. Asterisked mutations are not mapped onto the channel structures presented in [**Figures 9**](#f9){ref-type="fig"}--[**11**](#f11){ref-type="fig"} because those positions are not resolved in the final models. The Excel file for this table can be found as "[**Table 1**](#ST1){ref-type="supplementary-material"}" in the [**Supplementary Material**](#ST1){ref-type="supplementary-material"}.

### KCNQ1 {#s4_2_1}

KCNQ1 mutations studied to date are highly varied in molecular effects, with the potential to induce defects in channel stability, trafficking, electrophysiology, or all three ([@B44]; [@B91]; [@B311]; [@B27]). So far, a strong disposition for either expression or functional defects has not been elucidated. However, analysis of mutation sites points to regions of increased pathological risk and provides hints regarding prevalent mechanisms.

LQT1-associated mutations are found in every domain of the protein ([**Figure 9A**](#f9){ref-type="fig"}), particularly in the transmembrane channel domain ([@B254]; [@B189]; [@B126]). Mutations in the SF, ([**Figure 9A**](#f9){ref-type="fig"}, inset), VSD ([**Figure 9B**](#f9){ref-type="fig"}), and the S4--S5 linker ([**Figure 9C**](#f9){ref-type="fig"}) are especially prominent.

Mutations in and around the SF ([**Figure 9A**](#f9){ref-type="fig"}, inset) point to a potential ion permeation defect, as conformational changes may prevent potassium ion permeation and thus decrease the effective I~Ks~ current ([@B49]), as noted in several SF mutations ([@B112]; [@B272]; [@B33]; [@B46]). Molecular dynamics simulations of analogous mutations in KcsA indicated that mutations in the SF-interacting residues (including T322M, T322A, or G325R) may disrupt the organization of backbone atoms in the SF, abolishing K^+^ ion coordination and producing a dominant-negative effect on channel current ([@B33]).

VSD mutations are more common in KCNQ1 compared to hERG and SCN5A (see [**Figures 9B**](#f9){ref-type="fig"}, [**10B**](#f10){ref-type="fig"}, and [**11A**](#f11){ref-type="fig"}), indicating that the VSD is more important in LQT1. Analysis of LQTS mutations located in the VSD ([@B109]; [@B288]) indicate that loss of channel function was most commonly a consequence of mutation-induced destabilization of the channel, resulting in mistrafficking and lower surface expression. These results strongly correlated with Rosetta energy calculations of VSD mutants ([@B138]), supporting the importance of VSD destabilization as a LQT1 mechanism. A number of the deleterious mutations were found in the S0 helix and S0-contacting regions of the VSD. Among the 50 VSD mutations studied, the S0 mutations had the largest energetic destabilizations consistent with the large number of contacts formed between S0 and other regions of the VSD. ([@B109]; [@B138]). However, these studies also identified variants that did not exhibit folding and trafficking defects, but were either non-functional (low conductance) or dysfunctional, with modified gating, again pointing to a complex spectrum of LQT1 disease mechanisms.

Mutations in the KCNQ1 S4--S5 linker and its contacting regions ([**Figure 9C**](#f9){ref-type="fig"}) have the potential to perturb VSD-PD coupling and channel gating. Such effects have been demonstrated for a number of LQTS-associated mutations in the S4--S5 linker and the cytoplasmic end of S6, particularly for R243C, W248F/R, and Q357R, producing positive shifts in the voltage dependence of activation or inactivation and and/or decreased current amplitude ([@B72]; [@B30]; [@B190]). Because the S4--S5 linker is involved in both VSD/PD interactions and in binding of PIP~2~ ([@B63]; [@B263]) and KCNE1 ([@B124]; [@B315]; [@B55]), mutations in this region may affect gating either by weakening VSD-PD coupling or by hindering modulation by auxiliary molecules. Some LQT1 variant-induced changes in PIP~2~ binding at the S4--S5 linker have been noted (including R243H, R539W, and R555C) ([@B209]). Due to the complex nature of electromechanical coupling in KCNQ1 and the requirement for auxiliary subunits, a detailed structural understanding of mutation effects in this region is particularly challenging. However, the human KCNQ1, KCNQ1-KCNE3, and KCNQ1-KCNE3/PIP~2~ channel structures ([@B264]) may provide guidance in experimental design to elucidate LQT1-associated coupling defects in this region.

While the majority of LQT1 mutations map to the transmembrane domain, mutations are also found in the CTD, both in the HA/HB helix bundle, where CaM binds, and in the HC and HD coiled-coil domains ([**Figure 9A**](#f9){ref-type="fig"}). Mutations in HC and HD are particularly prevalent in sites of hydrophobic and electrostatic interactions that stabilize the coil, hinting at channel assembly defects ([**Figure 9D**](#f9){ref-type="fig"}). Defects in CaM binding and tetramerization cause some forms of LQT1, as demonstrated for several mutations ([@B125]; Ghosh S, 2006; [@B239]; [@B304]).

### hERG {#s4_2_2}

Loss-of-function mutations in hERG may lead to folding/trafficking defects, gating defects, or both ([@B10]; [@B258]; [@B27]). However, as many as 90% of hERG loss-of-function mutations appear to cause trafficking defects, independent of which domain is mutated ([@B258]). As in KCNQ1, pore domain mutations in hERG demonstrated stronger dominant-negative effects in hERG than other regions, hinting that mutations in this region are more severe ([@B10]).

Although hERG mutations span the entire protein, they are prominent in the SF ([**Figure 10A**](#f10){ref-type="fig"}, inset), the extracellular VSD/PD interface between S1 and S5 ([**Figure 10C**](#f10){ref-type="fig"}), and in the PAS and CNBHD cytoplasmic domains ([**Figure 10D**](#f10){ref-type="fig"}). Given the inherent instability of the hERG SF ([@B64]; [@B260]; [@B286]) and the functional necessity of the SF for fast inactivation ([@B95]; [@B99]), mutations may act by both affecting channel stability and inactivation. Inactivation defects due to LQT2-associated pore helix mutations have been identified ([@B332]; [@B217]). However, mutations in LQT2 more commonly cause misfolding and/or trafficking defects. Potassium ions appear to stabilize the mature hERG channel (possibly by interacting with the SF) to promote trafficking ([@B296]; [@B11]), with intracellular K^+^ depletion resulting in ER retention. G601S mimicked this phenotype ([@B11]). G601S, a mutation in the pore loop near the SF, mimicked also impedes trafficking through enhanced chaperone association in the ER ([@B70]), supporting the idea of SF destabilization as a cause for channel mistrafficking. A detailed understanding of mutations in the SF region requires both intensive structural and cellular analysis to uncover not only protein conformational changes upon mutation, but also cellular quality control responses to these changes.

The VSD of hERG has fewer pathogenic mutations than that of KCNQ1 ([**Figure 10B**](#f10){ref-type="fig"}), perhaps an indication that the hERG VSD has a higher folding stability. Indeed, when a set of hERG VSD mutations were assessed for membrane insertion efficiency, the majority of mutations were predicted to have no change in the free energy of insertion ([@B10]). However, there are a surprising number of disease mutations at the extracellular interface between S1 and S5, specifically at the A422, P426, Y427, S428, H562, W563, C566, and Y569 positions ([**Figures 10B, C**](#f10){ref-type="fig"}). This interface has not been studied extensively. However, we speculate that it may be important to channel stability by providing an additional contact surface between the VSD and the PD distinct from the S4--S5 linker. Destabilization of this interface may therefore lead to mistrafficking. Mutation Indeed, A422T results in ER retention but was rescued with a pharmacological chaperone ([@B85]). Other mutations in S1 alter gating properties in addition to trafficking ([@B10]; [@B214]), indicating that gating properties may also be affected. Further studies are needed to determine the impact of mutations in this interface on folding, trafficking, and gating properties of hERG.

A number of mutations are found in the PAS and CNBHD, particularly in the PAS and at the interface between the two domains ([**Figures 10A, D**](#f10){ref-type="fig"}). The structural stability of both domains impacts trafficking ([@B8]; [@B89]; [@B128]; [@B129]), and several trafficking-defective mutants have been characterized at the PAS/CNBHD interface (F29L, I31S, I42N, Y43C, R56Q, M124R), suggesting that occlusion of a PAS hydrophobic patch from the cytoplasm through interaction with the CNBHD is critical for proper trafficking ([@B128]). Trafficking defects due to destabilization of the PAS, the CNBHD, or their interaction may thus be a prominent mechanism in LQT2. The direct interaction of these two domains has also been implicated in slow deactivation of the channel ([@B199]; [@B139]), as deactivation defects have been noted in channels with mutations at this interface ([@B10]). Deactivation defects may be a secondary source of LQT2. Detailed structural analysis of mutation-induced destabilization of the PAS and the CNBHD as well as studies of cellular responses to PAS/CNBHD destabilization would be highly informative to our understanding of LQT2. Indeed, similar studies have already revealed differential cellular responses to LQT2 PAS mutations, depending on the severity of PAS destabilization ([@B71]).

### SCN5A {#s4_2_3}

LQT3 mutations induce channel gain-of-function in SCN5A ([@B305]; [@B256]). Accordingly, mutations that interfere with SCN5A folding and trafficking do not cause LQT3 ([@B27]; [@B305]). The primary mechanism leading to LQT3 is rather impairment of fast inactivation ([@B27]; [@B305]). The results of our analysis are consistent with this notion. The site where the S5 and S6 helices of repeats III and IV cross, in the binding pocket for the IFM motif, contains the majority of the mutations curated in this study ([**Figures 11A, C**](#f11){ref-type="fig"}). These mutations may impact interaction of the IFM motif with other channel structures, hindering fast inactivation and generating a persistent sodium current. For instance, A1326 (A1328 in rSCN5A) and G1329 (G1331 in rSCN5A) make critical backbone interactions to help form a tight hydrophobic pocket for IFM interactions ([@B116]). Mutations A1326P and G1329S ([**Table 1**](#T1){ref-type="table"}) may thus compromise the stability of this pocket, hindering inactivation. Additionally, S6 mutations surrounding this putative inactivation gate also map to the constriction site of the channel pore, with additional mutations in S6~I~ and S6~II~ ([**Figure 11D**](#f11){ref-type="fig"}). It has been proposed that binding of the IFM motif causes a rotation in the S6 helices that closes the pore ([@B319]). Therefore mutations in S6 may also alter inactivation by preventing helix rotation. Indeed, residues important to defining the constriction site of the Na~v~1.7 pore cause LQTS upon mutation in SCN5A (L398 and Y1755) ([@B252]). A few mutations also map to the CTD of SCN5A ([**Figure 11B**](#f11){ref-type="fig"}), which could alter interactions with the III/IV linker and hinder fast inactivation.

The recent structure of the rat homolog of SCN5A ([@B116]) suggests another gain-of-function mechanism, namely that VSD mutant R225P could promote current leak through the VSD (gating pore current). Experimental evidence supporting this mechanism exists for other SCN5A ([@B184]) and Na~V~1.4 ([@B259]) VSD mutations.

Structural Basis for Channel Pharmacology {#s5}
=========================================

Pharmacological management of LQTS aims to minimize symptomatic arrhythmia and prevent life-threatening cardiac events. According to consensus guidelines ([@B336]; [@B219]), treatment with β-blockers is beneficial and effective in the case of LQTS diagnosis, but should be considered only after additional diagnostics for carriers of LQTS mutations. β-blockers work by inhibiting β-adrenergic receptors, consequently slowing heart rate and preventing arrhythmias triggered by activation of the sympathetic nervous system ([@B27]). However, the efficacy of β-blockers is strongly genotype- and trigger-specific ([@B188]; [@B240]; [@B27]). β-blockers reduce the risk of exercise-induced arrhythmia by 78% and 71% in patients with LQT1 and LQT2, respectively, but neither are protective against cardiac events triggered by emotional arousal or during rest ([@B132]; [@B81]). Patients with LQT3 tend to experience the highest breakthrough rate for cardiac events (10--15%) with β-blocker treatment ([@B79]). Use of local anesthetic-type anti-arrhythmic agents (e.g. mexiletine) for clinical treatment of LQT3, however, can be accompanied by undesirable side effects ([@B185]). The need for improved LQTS pharmacotherapy is further supported by the difficulties surrounding hERG modulation, as several clinically-used drugs can cause drug-induced LQTS by blocking hERG and suppressing I~Kr~ ([@B286]; [@B120]). This section summarizes some known pharmacological agents and the modes of interaction with KCNQ1, hERG, and SCN5A. Special focus is dedicated toward unique structural features of hERG that have been implicated in the promiscuity of this channel for pro-arrhythmic drugs.

KCNQ1 {#s5_1}
-----

KCNQ1 channels are targeted by several non-selective anti-arrhythmic drugs such as quinidine ([@B12]), amiodarone ([@B12]; [@B121]), azimilide ([@B34]), and clofilium ([@B320]). More specific KCNQ1 blockers include chromanol 293B ([@B29]), and the benzodiazepine L-735821 ([@B146]). The binding site of L-735821 has been located to the SF and S6 ([@B243]).

Benzodiazepine R-L3 was the first KCNQ1 activator to be described. The compound acts to slow the deactivation rate and causes a hyperpolarizing shift in the voltage-dependence of channel activation ([@B233]). R-L3 appears to bind residues on S5 and S6 lining the membrane-exposed surface of the PD ([@B244]) rather than to the inner channel cavity. Drug binding outside of the PD cavity was also reported for quinidine ([@B321]), which occupies a pocket between S6 and the S4--S5 linker and is postulated to elicit an allosteric channel blocking mechanism. More recently, ML277 was identified as a potent KCNQ1 agonist ([@B170]). ML277 has been proposed to bind to a side pocket surrounded by the S2--S3 and S4--S5 linkers on the intracellular side and helices S4 and S6 on the intramembrane lateral side ([@B316]). Binding of ML277 may selectively alter VSD/PD coupling to stabilize the AO state relative to the IO state ([@B103]).

hERG {#s5_2}
----

hERG channels can be blocked by a wide spectrum of compounds, leading to drug-induced LQTS ([@B53]). The list of drugs that inhibit hERG includes, among others, antibiotics (grepafloxacin ([@B26])), antihistamines (astemizole ([@B333])), anti-arrhythmics (quinidine ([@B229]), dofetilide ([@B119])), antipsychotics (sertindole ([@B226])), and gastroprokinetic agents (cisapride ([@B291])) ([**Figure 12A**](#f12){ref-type="fig"}). Several prescription drugs have been withdrawn from the market because of cardiotoxic side effects triggered by off-target interaction with hERG ([@B120]). In fact, an estimated 15% of drugs still on the market may cause QT phase prolongation, and 60% of drugs in development show hERG liability ([@B287]). It is now required by the US FDA that all compounds considered for advancement to clinical trials be tested for their impact on hERG channel function as part of preclinical toxicity assessments ([@B110]; [@B111]).

![Structural features of the drug-binding cavity of the hERG channel pore. **(A)** Examples of drugs discontinued by the US FDA because of side effects related to hERG inhibition (adapted from [**Table 1**](#T1){ref-type="table"} in ([@B120])). **(B)** Internal molecular surface of the central cavity below the SF in hERG (PDB: 5VA1)([@B294]) (top) and the K~V~1.2--2.1 chimeric channel (PDB: 2R9R)([@B158]) (bottom). The surface is colored by the electrostatic potential calculated with the APBS tool in PyMOL (The PyMOL Molecular Graphics System, Version 2.2 Schrödinger, LLC.). Residues related to drug binding by hERG and the corresponding residues in the K~V~1.2--2.1 structure are shown as sticks. This panel is inspired by [**Figure 5**](#f5){ref-type="fig"} in ([@B294]).](fphar-11-00550-g012){#f12}

Considerable progress has been made in understanding the basic features of drug binding to hERG, and a plausible mechanism for promiscuity of drug binding has emerged. Pro-arrhythmic drugs commonly bind to the central inner cavity of the PD in hERG. Two pore-lining aromatic residues in S6 (Y652 and F656) are the most crucial for drug binding ([@B180]), although additional residues at the end of the pore helix (T623, S624, and V625) contribute to binding for some drugs ([@B180]), and mutations at F557 in the S5 helix can also affect binding ([@B235]). The side chains of the S6 and pore helix residues point towards a putative drug binding site located in the central cavity below the SF. This cavity is slightly narrower in hERG than in the Shaker family K~V~1.2--2.1 chimeric channel ([@B158]). As a consequence, there is a greater negative electrostatic potential in this region ([@B294]), which could enhance drug binding capabilities ([**Figure 12B**](#f12){ref-type="fig"}). In addition, four lateral hydrophobic pockets, which are not observed in the K~V~1.2--2.1 structure, extend outwards from that central constriction site, generating additional space to trap chemical moieties ([@B294]).

Quantitative structure-activity relationship studies have identified a pharmacophore for drugs that bind to hERG ([@B38]). The pharmacophore consists of three centers of mass (usually aromatic rings) and an amino group that together form a flattened tetrahedron. It has been suggested that the aromatic rings could fit into one or more lateral hydrophobic pockets in hERG and/or bind by pi-pi stacking or hydrophobic interactions with Y652 and F656 ([@B43]). Likewise, the greater negative electrostatic potential in the central cavity could explain why many drugs that bind hERG, including off-targets, contain a positive charge ([@B67]). Additionally, a number of docking models for drug-bound hERG, with and without this pharmacophore, are being generated ([@B292]; [@B93]; [@B197]), making possible further delineation of drug binding modes within this pocket and the structural basis of their affinity for hERG.

The majority of high-affinity drugs that bind hERG off-target preferentially bind to the inactivated state rather the open state, with affinity differences ranging from 2- to 100-fold ([@B210]). Interestingly, the related EAG1 channel ([@B303]) is less sensitive to inhibition by most of hERG-blocking drugs even though they share the same pore-lining aromatic residues. One major difference between hERG and EAG1 is that EAG1 channels undergo minimal inactivation ([@B75]) whereas hERG channels undergo rapid and complete inactivation ([@B286]). The contribution of inactivation to high-affinity binding is further substantiated by the observation that inactivating EAG1--hERG chimeras, containing the upper half of the hERG PD, can bind drugs with almost hERG-like affinity ([@B95]). While cryo-EM structures have been determined for both hERG and EAG1 ([@B303]; [@B294]), the structural basis of the functional and pharmacological differences requires higher resolution ([@B294]).

SCN5A {#s5_3}
-----

Limited progress has been made in the development of SCN5A-targeted treatment strategies. Classical non-selective sodium channel blockers like the Vaughan-Williams class I anti-arrhythmic drugs quinidine, lidocaine, and propafenone have only limited clinical applicability. Ranolazine is a more selective SCN5A blocker ([@B19]; [@B328]) and has been shown to attenuate action potential duration and reduce or prevent intracellular calcium overload in LQT3 models ([@B307]; [@B154]). Mexiletine is a potent inhibitor of SCN5A and may be beneficial for treatment of LQT3 ([@B172]), but effectiveness may depend on the baseline QT prolongation of the mutant channel ([@B147]).

Despite the clinical relevance of SCN5A-targeting drugs, the molecular mechanisms of promising and potentially problematic drugs are not well understood at a structural level, hindering drug design. However, key residues for apparent drug binding have been suggested within the sodium channel pore domain. Specifically, mutations of two conserved aromatic residues in S6~IV~, F1760 and Y1767, ([@B223]; [@B224]) or other S6 residues in repeats I and III ([@B323]; [@B324]) may affect drug binding. Using fluorinated phenylalanine derivatives incorporated at F1760 ([@B215]), a strong cation-pi interaction between F1760 and the protonated amine group in class Ib anti-arrhythmic drugs was observed, defining the molecular basis for inhibition of SCN5A by this group of drugs. Additionally, mutations within the SF region can affect apparent drug binding either by enhancing slow inactivation or forming an alternative access pathway ([@B265]; [@B142]; [@B279]). Interactions of anti-arrhythmic and local anesthetic drugs (lidocaine, QX-314, etidocaine, flecainide, and ranolazine) docked into an inactivated state model of SCN5A ([@B200]) revealed several key drug binding sites in the inner pore lumen that can simultaneously accommodate up to two drug molecules. Subsequent MD simulations suggested alternative access mechanisms for drugs into the SCN5A lumen -- a hydrophilic pathway through the intracellular gate and a hydrophobic pathway through a membrane-exposed fenestration between repeats III and IV.

The recent structure of rat Na~v~1.5 ([@B116]) has provided insight into the binding mode of the class Ic anti-arrhythmic drug flecainide, which has higher affinity for the open conformation of SCN5A ([@B225]). Flecainide binds in the central cavity on the intracellular side of the SF. The piperidine ring of flecainide lies across the top of the central cavity with the positively-charged nitrogen pointing towards the exit of the SF and its hydrophobic edge extending towards the phenyl ring of F1762 (F1760 in human Na~v~1.5). The trifluoroethoxy tails of flecainide extend into fenestrations formed between the pore helices of repeats I and II as well as repeats II and III, through which the central cavity is accessible from the lipid bilayer. These fenestrations represent possible entry points for flecainide and similar class Ic drugs.

Future Directions {#s6}
=================

The growing number of structural and functional studies of KCNQ1, hERG, and SCN5A have provided new insight into channel molecular physiology and channel dysfunction in congenital LQTS. This further motivates the study of fundamental biophysical mechanisms in ion channels. One of these mechanisms, electromechanical coupling, remains enigmatic due to a dearth of experimental resting state structures and robust methods to identify allosteric pathways, which cannot easily be discerned from ion channel structures resolved in a single conformation. However, interaction energy and MD dynamical network analysis in the Shaker K^+^ channel ([@B68]) has suggested that movements in the VSD and PD are linked by two distinct pathways -- a canonical pathway through the S4--S5 linker and a hitherto unknown non-canonical pathway involving contacts at the interface between S4 and S5. Such work may provide a useful alternative approach to explore electromechanical coupling in detail.

Another major effort involves the experimental characterization of hundreds of previously uncharacterized variants of unknown significance (VUS) and LQTS mutations in KCNQ1, hERG, and SCN5A. Widespread use of whole genome and exome sequencing has provided a nearly complete catalog of common sequence variations in protein-coding genes ([@B144]), although rare sequence variants continue to be discovered. For many LQTS mutations, the molecular mechanisms responsible for impaired channel function remain poorly understood. Such mutations may cause potassium channel loss-of-function or dysfunction by promoting misfolding, mistrafficking, aggregation, or improper gating of the channel protein, as discussed above. Continued experimental testing will be required to complete functional annotation of KCNQ1, hERG, and SCN5A variants and to elucidate how these mutations lead to channel dysfunction. In this regard, new techniques such as high-throughput patch clamp recording ([@B288]; [@B277]), which allows rapid screening of ion channel variants found in patients, and the use of induced-pluripotent stem cell-derived cardiomyocytes ([@B186]; [@B165]; [@B270]; [@B118]) developed from cells of healthy or mutation-carrying patients, represent helpful tools for large-scale examination of ion channel variants.

Finally, experimentally-informed bioinformatics and modeling approaches are being developed to predict variant pathogenicity ([@B135]; [@B149]; [@B137]). These computational algorithms can help to decrypt newly discovered VUS for which there is not enough data to determine pathogenicity. Decrypting VUS can inform medical practice and has the potential to improve LQTS therapy, both for the prevention of cardiac events in susceptible patients and as a basis for avoiding unneeded treatment in healthy patients. With improved understanding of the molecular pathophysiology and the role of mutations associated with distinct LQTS subtypes, the ultimate hope is that identifying a patient's genotype will lead to more specific treatment considerations and the delivery of optimal care.

Author Contributions {#s7}
====================

KB and GK wrote the primary draft of this article, with edits by KB, GK, JM, CV, AG, and CS. KB and GK contributed equally to this manuscript.

Funding {#s8}
=======

This work was supported by US NIH grant RO1 HL122010. GK was supported by a postdoctoral fellowship from the American Heart Association (18POST34080422) and KB was supported by NIH training grant T32 GM008320.

Conflict of Interest {#s9}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material {#s10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00550/full#supplementary-material>

###### 

LQTS mutations in KCNQ1, hERG, and SCN5A.

###### 

Click here for additional data file.

[^1]: Edited by: Mounir Tarek, Centre National de la Recherche Scientifique (CNRS), France

[^2]: Reviewed by: Sergei Noskov, University of Calgary, Canada; Clemens Möller, Hochschule Albstadt-Sigmaringen, Germany

[^3]: This article was submitted to Pharmacology of Ion Channels and Channelopathies, a section of the journal Frontiers in Pharmacology

[^4]: †These authors have contributed equally to this work
